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Abstract 
 
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease associated with 
significant morbidity and early mortality. Despite this, the pathogenesis remains poorly 
understood and there is no effective disease modifying treatment. Epidemiological 
studies demonstrate an association between IPF and vascular disease. Platelets and 
the endothelium play an important role in maintaining vascular integrity, patency and 
function. In addition to their role in haemostasis, platelets have significant 
inflammatory and pro-fibrotic potential. Platelets and the lung have a close 
relationship in physiology and in disease however the role of platelets in IPF has not 
previously been investigated. 
In this thesis we investigate the link between IPF and vascular disease and consider a 
potential pathogenic role of platelets in IPF. We do this through the following series of 
experiments: (1) investigation of the platelet endothelial cell adhesion molecule-1 
single nucleotide polymorphisms in IPF and controls; (2) assessment of markers of 
platelet activation in IPF and controls; (3) investigation of the effect of IPF plasma on 
control platelets; (4) assessment of platelet function by measurement of platelet-
endothelial cell adhesion; and (5) evaluation of plasma markers of endothelial 
activation and fibrinolysis in IPF.  
We demonstrate that IPF patients exhibit increased platelet reactivity and that this can 
be reproduced in control platelets following incubation in IPF plasma suggesting that a 
plasma factor is responsible for this phenomenon. In addition, we show that the 
increased platelet reactivity in IPF is associated with an increased propensity to adhere 
to vascular endothelium confirming abnormal platelet function in IPF patients and 
suggesting a potential pathogenic mechanism. We do not demonstrate any difference 
in plasma levels of endothelial activation markers or fibrinolysis between IPF patients 
and controls. Similarly, we find no clinically significant difference in the prevalence of 
the PECAM-1 polymorphisms in IPF and controls.  
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1. Background 
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial 
pneumonia (IIP) and carries a prognosis worse than many cancers with newly 
diagnosed patients having a median life expectancy of 2.8 years (1). Current 
classification defines IPF as the histological subtype of IIP, usual interstitial pneumonia 
(UIP). Patients typically experience symptoms of progressive shortness of breath with 
or without a dry cough. The progressive nature of this disease results in profound 
morbidity and early mortality. Despite the significant burden that this disease places 
on affected individuals it remains poorly understood and without effective disease 
modifying treatment.  
There have been significant changes in IPF research over the years with reclassification 
of the disease taking account of non-specific interstitial pneumonia (NSIP) as a distinct 
clinical entity with a different clinical course and better prognosis than UIP. As such, 
historical studies of IPF (also known as cryptogenic fibrosing alveolitis) grouped a 
number of the IIP under a single umbrella term and therefore must be interpreted 
carefully when drawing conclusions applicable to current practice. It is also important 
to note that the pathological appearance of UIP is not unique to IPF and is also 
observed in interstitial lung disease associated with asbestos exposure, 
hypersensitivity pneumonitis and the connective tissue diseases(2).  
There has been a shift in hypothesis regarding the pathophysiology of IPF away from a 
model of chronic inflammation precipitating fibrosis to a new model where initial 
epithelial and or endothelial injury results in aberrant wound healing/tissue repair. 
There has been a resulting change in the focus of scientific research with recent 
advances resulting in appreciation of the process of epithelial mesenchymal 
transformation in IPF and discovery of the circulating fibroblast precursor of bone 
marrow origin termed the fibrocyte.  
An interesting discovery in recent years is the association between vascular disease 
and IPF. An increased rate of ischaemic heart disease and thromboembolic disease has 
been observed in patients prior to and following the diagnosis of IPF (3;4). This leads to 
important questions about what links these conditions and poses challenges regarding 
chronology and causality. The endothelium and haemostatic mechanisms are 
 13 
important in both cardiovascular disease and venous thromboembolic disease and 
may also be of importance in IPF. It is well established that platelets and the lung are 
closely linked in physiology and indeed in pathology. Markers of endothelial activation 
and endothelial autoantibodies have been described in IPF and polymorphisms and 
serum levels of platelet endothelial cell adhesion molecule-1 (PECAM-1) have been 
implicated in cardiovascular disease in humans and pulmonary fibrosis in a mouse 
model. For this reason it is important to further investigate the role of the 
endothelium, platelets and haemostatic mechanisms in IPF. 
The series of experiments described in this thesis aim to investigate platelet, 
endothelial and haemostatic responses in IPF patients compared with control patients 
without fibrotic lung disease. The results of these experiments will be discussed in 
their respective chapters following a review of the literature regarding IPF and its links 
to the vasculature.  
1.1 Disease Classification 
Hamman and Rich published a case series in 1935 describing a number of patients 
presenting to John Hopkins Hospital with diffuse parenchymal lung disease with 
variable stages of fibrosis evident on autopsy (5). This case series represents an early 
description of interstitial lung disease, in particular IIP. Our understanding of this group 
of lung diseases has progressed greatly since this time and continues to evolve; 
however, until recently there has not been a consensus on the classification of this 
heterogenous group of disorders. 
IPF is the most common interstitial lung disease. Formerly also known as cryptogenic 
fibrosing alveolitis (CFA), the definition of this interstitial lung disease has changed in 
recent years with the publication of the ‘International Multidisciplinary Consensus 
Classification of the Idiopathic Interstitial Pneumonias by the European Respiratory 
Society (ERS) and American Thoracic Society (ATS) in 2002(6). The evolution of the 
classification of the IIP’s is presented in table 1.  
The IIP’s were initially classified by Liebow in 1968 describing 5 histological subtypes: 
usual interstitial pneumonia (UIP), desquamative interstitial pneumonia (DIP), 
bronchiolitis with interstitial pneumonia, lymphoid interstitial pneumonia (LIP), and 
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giant cell interstitial pneumonia (GIP). This classification was updated in 1997 by 
Muller and Colby with the exclusion of LIP because it was felt to represent a 
lymphoproliferative disorder and GIP which was discovered to be pneumoconiosis 
(6;7). Despite the classification of the IIP’s by histological sub-type there remained 
widespread grouping of UIP, NSIP and DIP under the umbrella terms IPF or CFA 
including in the 1999 British Thoracic Society Guidelines (7). However, in 2002 the 
ATS/ERS published the consensus that defines the current classification of this group of 
interstitial lung diseases. In this classification the terms IPF or CFA refer only to UIP 
with NSIP and DIP becoming independent clinical entities (2;6). The British Thoracic 
Society (BTS) adopted this approach in their 2008 guidelines, discarding the term CFA 
and adopting IPF as described in the ATS/ERS consensus (2).  
The international acceptance of the ATS/ERS consensus classification has reduced the 
ambiguity in terminology that plagues the historic literature making it easier to 
interpret and apply current research findings to clinical practice. The diagnostic criteria 
for IPF were further revised in 2011 in a joint statement from the ATS, ERS, Japanese 
Respiratory Society (JRS) and the Latin American Thoracic Association (ALAT) (8) but 
the main principles and classification remain unchanged from the 2002 consensus (9).  
1.2 Clinical Course of IPF  
The clinical course of IPF can vary widely ranging from rapidly progressive shortness of 
breath and dry cough with early mortality to asymptomatic fibrotic change noted 
incidentally on plain chest x-ray. Examination findings vary and can include finger 
clubbing and ‘velcro-type’ inspiratory crackles at both lung bases. The diagnosis is 
multidisciplinary based on clinical presentation, lung function testing and high 
resolution computed tomography (HRCT) appearance with lung biopsy reserved for 
cases in which there is diagnostic uncertainty (2).  
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Liebow 1968* Mϋller 1997* ATS/ERS 2002** 
Usual interstitial 
pneumonia 
Desquamative interstitial 
pneumonia 
Bronchiolitis with 
interstitial pneumonia 
Lymphoid interstitial 
pneumonia 
Giant cell interstitial 
pneumonia 
 
Usual interstitial 
pneumonia 
Desquamative interstitial 
pneumonia 
Bronchiolitis obliterans with 
organizing pneumonia 
(BOOP/COP) 
Acute interstitial 
pneumonia 
Non-specific interstitial 
pneumonia 
(Lymphoid interstitial 
pneumonia and giant cell 
interstitial pneumonia no 
longer included as felt to 
represent a 
lymphoproliferative 
disorder and 
pneumoconiosis 
respectively.)  
Idiopathic pulmonary 
fibrosis (UIP) 
Non-specific interstitial 
pneumonia 
Cryptogenic Organizing 
pneumonia 
Acute interstitial 
pneumonia 
Respiratory bronchiolitis 
interstitial lung disease 
Desquamative interstitial 
pneumonia 
Lymphoid interstitial 
pneumonia 
Table 1. Evolution of Classification of IIP 
*See reference (7) 
** see reference (6) 
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1.3 Epidemiology of IPF 
Our understanding of the epidemiology of IPF has improved in recent years with a 
growth in the number of published epidemiological studies. Limitations relating to the 
use of large population data sets and historical changes in disease classification have to 
be considered when interpreting the data. A study of the incidence and mortality of 
IPF in the United Kingdom (UK) utilised a computerised General Practice database (the 
Health Information Network) containing information from 255 centres throughout the 
country (10). It reported an incidence rate of 4.6 per 100,000 person-years with a 
mean age of 71 years at diagnosis and male predominance (62%). There was significant 
geographical variation in incidence rates being higher in Scotland and the North of 
England and there was an overall rise in incidence by 11% per year throughout the 
study period. The median survival in this cohort was 3.9 years (10). A more recent UK 
study utilising the Health Information Network in addition to mortality data published 
by the Office of National Statistics reported rising incidence of IPF from 5.77 per 
100,000 person-years in 2000 to 8.04 per 100,000 person-years in 2008 (11). Mortality 
attributed to IPF was also found to have increased over time from 0.92 per 100,000 
person-years in 1968-1972 to 5.10 per 100,000 person-years in 2005-2008. The 
incidence and mortality rates were highest in men and with increasing age (11). Similar 
trends have been observed in hospital admission rates due to IPF in the UK with a 5% 
annual increase per year between 1998 and 2012 (12). Another European study 
assessed all pulmonary clinics in Finland and estimated a nationwide prevalence of 16-
18 cases per 100,000 with familial cases accounting for 3-4% (13).  
A retrospective cohort study carried out in the United States (US) estimated an 
incidence of 16.3 per 100,000 people and a prevalence of 42.7 per 100,000 people by 
extrapolating data from a cohort of 2.2million people in 20 states who had made 
claims through a large US health plan provider(14). These figures are based on 
evaluation of the number of patients with one or more encounters coded as IPF in the 
absence of any other encounters coded as a different interstitial lung disease. The 
authors referred to this as the ‘broad definition’. Narrowing the diagnostic criteria to 
include only those with procedure codes for surgical lung biopsy, transbronchial biopsy 
or CT thorax (‘narrow definition’) reduced the estimated incidence and prevalence of 
IPF to 6.8 and 14 per 100,000 people respectively. Based on the ‘broad definition’, the 
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prevalence increased with age from 4 per 100,000 people under 34 years to 227 per 
100,000 people over 75 years (14). In light of this association with increasing age the 
ATS/ERS criteria for diagnosis of IPF in the absence of surgical lung biopsy includes age 
>50 years as a minor criteria (2). A male predominance was also noted in the American 
cohort in keeping with the findings in the UK study however this was not confirmed in 
the Finnish population.  
There is an association with smoking with an odds ratio of 1.6 for people who had ever 
smoked, increasing for current smokers and those with higher cigarette 
consumption(15). A survey of 1,442 patients with IPF in the US reported a history of 
cigarette smoking in 68.9% with 3.2% continuing to smoke (16). A history of smoking 
has a negative impact on prognosis with reduced severity-adjusted survival (17).  IPF 
has been associated with a number of other conditions including gastroesophageal 
reflux (14;16;18); cardiovascular disease (3); and deep vein thrombosis (DVT) (4).  
Gastroesophageal reflux (GER) is prevalent in the general population with a survey of 
2,200 individuals aged 25-74 years in the US reporting approximately 20% of 
individuals experience symptoms of heartburn or acid regurgitation at least once 
weekly (19). An association between GER and fibrotic lung disease has been described 
for many years (20;21) however it is only recently that with the development of 
technology allowing assessment of oesophageal physiology that the relationship has 
been further investigated. Raghu et al. (22) performed a prospective study of 65 IPF 
patients and 133 controls with intractable asthma in order to assess the prevalence of 
GER in this group. They found a significantly greater prevalence of GER in the IPF group 
with 87% of patients having GER on oesophageal physiology studies but only 47% 
reporting typical reflux symptoms. The percentage of proximal and distal reflux time 
did not however correlate with IPF severity (22). Imaging studies have demonstrated 
that hiatus hernia, a condition associated with GER, is more prevalent in IPF patients 
compared with patients with other respiratory diseases (23). GER has also been found 
to be associated with acute exacerbations in IPF patients (24). Examination of 
bronchoalveolar lavage (BAL) specimens in a case-control study of IPF patients with 
acute exacerbations compared with controls with stable disease found that pepsin, 
indicating aspiration of gastric contents, was an indicator of acute exacerbation status 
in these patients (24). Interestingly, IPF patients with asymmetrical disease on HRCT 
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have been shown to have a significantly increased rate of GER and acute exacerbations 
compared to IPF patients with symmetrical disease (25). In this study, the method of 
diagnosing GER was the presence of symptoms with or without evidence of reflux on 
endoscopy or PH studies (25). Asymptomatic GER is common in IPF patients (22) and 
therefore the rate of GER may have been underestimated. There is some suggestion 
that treatment of GER in IPF patients may improve outcome. The use of GER 
treatments consisting of acid suppression at the time of IPF diagnosis was associated 
with less fibrosis on HRCT and increased long-term survival in a retrospective study 
(26). Although the retrospective nature of this study limits the strength of its 
conclusions it does provide support to the hypothesis that GER contributes to lung 
injury in IPF and emphasises the need for a prospective, randomised-controlled trial of 
GER treatment in IPF. Although GER with microaspiration and resulting lung injury 
represents an attractive hypothesis for inducing pulmonary fibrosis, the temporal 
relationship remains unclear with questions remaining whether GER is the primary 
event leading to IPF or simply results from the increased negative intrathoracic 
pressure that results from reduced compliance of fibrotic lungs. 
A population-based study in the UK used the Health Information Network to assess the 
relationship between IPF and cardiovascular disease (3). This study included 920 IPF 
patients and 3,593 age, sex and community matched controls. An increased rate of 
vascular events including acute coronary syndrome, angina, and DVT were observed in 
the years preceding the diagnosis of IPF compared with the control group. This 
increased rate continued following diagnosis with an incidence of new acute coronary 
events of 19.3 per 1,000 person-years in the IPF group compared with 8.5 per 1,000 
person-years in control subjects. Similarly, the rate of DVT was significantly greater 
following IPF diagnosis with 5.9 per 1,000 person-years compared to 2.1 per 1,000 
person-years in controls. The findings of this study were not explained by differences 
in demographic or smoking status. Therefore, there is evidence that IPF patients have 
a higher rate of vascular events than age and sex matched controls and that this 
association precedes the diagnosis of IPF.  
The association between vascular events and IPF has been further assessed in a 
nationwide study of the Danish population over a 27-year period comprising almost 
7.5million people (4). This study utilised the Danish Patient Registry and Danish Causes 
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of Death Registry in order to identify patients with IIP and patients with venous 
thromboembolic disease including DVT and pulmonary embolism (PE). The risk of 
developing IIP was significantly higher in individuals with a previous history of venous 
thromboembolism (VTE) with an incidence of 18 per 100,000 person-years compared 
with 8 per 100,000 person-years in individuals with no history of VTE. The incidence of 
IIP was highest in those with a previous history of PE (28 per 100,000 person-years)(4). 
This association has also been demonstrated in a cohort of over 45 million individuals 
of whom 218,991 satisfied the criteria for a diagnosis of IPF (27). IPF was associated 
with a 34% higher risk of VTE compared with the general population with death 
occurring at a younger age in IPF patients with previous VTE versus those with no 
history of VTE (27).  
These studies confirm an association between vascular events and IPF however the 
nature of the relationship remains unclear. It is clear that further research is required 
to improve our understanding of the pathophysiology of IPF in order to better define 
the relationship between IPF and vascular disease.  
1.4 Pathophysiology of IPF 
The initial hypothesis that chronic inflammation was central to the pathogenesis of IPF 
led to traditional treatment strategies targeting this process. Despite this disease 
having a prognosis worse than many cancers, until recently there has been a paucity of 
evidence regarding the proposed therapies with a meta-analysis by the Cochrane 
Collaboration in 2003 studying the use of corticosteroids in IPF failing to find any 
randomised clinical trials or controlled clinical trials for inclusion (28). Based on current 
evidence, the treatment regimens based on corticosteroids and other 
immunosuppressant medications have largely proved ineffective in altering the natural 
disease progression and resulting mortality and indeed may be harmful(29;30). 
Evidence from an early study reported that the addition of acetylcysteine to the 
regimen of corticosteroids and azathioprine slowed the deterioration of lung function. 
However, this study was underpowered to demonstrate any mortality benefit and only 
carried a weak recommendation in guidelines (2;31). Subsequently, a large 
randomised, placebo-controlled trial of prednisolone plus azathioprine plus 
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acetylcysteine was stopped early due to increased mortality, largely due to 
deterioration of lung disease, in the treatment arm (30).  
New therapies are under investigation with some promising initial results from 
Pirfenidone; a novel agent that has anti-inflammatory, antioxidative and antifibrotic 
effects. Early trials have demonstrated a reduced decline in lung function and 
decreased incidence of acute exacerbations in the treatment group versus controls 
(32-34). The tyrosine kinase inhibitors are also undergoing investigation in IPF. An early 
study of Imatinib in IPF was disappointing, failing to demonstrate any benefit in lung 
function or survival in the intervention arm (35). However, a recent phase 2 trial of the 
new tyrosine kinase inhibitor BIBF1120, although failing to meet its primary end-point 
of reduced rate of FVC decline, did demonstrate a reduced decline of FVC from 
baseline, a reduction in acute exacerbations and a modest improvement in the St 
George Respiratory Questionnaire with the highest dose of the study drug (36). 
Despite these recent advances, there remains no widely accepted disease modifying 
treatment for patients with IPF. In exploring new avenues of treatment it is necessary 
to improve our understanding of the underlying disease process including its aetiology 
and pathogenesis.  
Over recent years there have been significant changes in our understanding of the 
pathogenesis of this condition. The focus has moved from the classical hypothesis 
suggesting a central role of chronic inflammation towards a new hypothesis of 
epithelial and/or endothelial injury with abnormal tissue repair/wound healing (37). 
Recent advances have led to the belief that pulmonary fibrosis develops following 
initial lung injury with loss of the integrity of the alveolar-capillary basement 
membrane. Subsequent failure of re-epithelialisation and re-endothelialisation with 
cytokine mediated fibroblast and myofibroblast proliferation leads to collagen 
deposition (37). Several cytokines have been implicated in this process including 
platelet-derived growth factor (PDGF) (38-40), transforming growth factor-  (TGF- ) 
(41;42) insulin-like growth factor (39) and interleukin-1  (Il-1 ) (43).  
However, the role of inflammation in IPF has not been exhaustively investigated and 
there remains debate over its involvement. Indeed, NSIP has been demonstrated to 
coexist with UIP in 26% of individuals with IIP undergoing lung biopsy as part of a 
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prospective investigation of the histological variability in surgical lung biopsies from 
multiple lobes (44). Ground-glass opacification on HRCT (thought to represent 
inflammation on HRCT) is a feature of NSIP, which is also believed to be more steroid 
responsive than UIP. These findings pose the question whether NSIP, in which 
inflammation is a feature, represents an earlier stage in the disease process that when 
untreated progresses to the pathological appearance of UIP. Also, caution must be 
exercised when dismissing a role for inflammation based on the lack of efficacy of 
immunosuppressant regimes containing corticosteroids. This approach disregards the 
possible negative effects of corticosteroids. Corticosteroids reduce alveolar cell 
proliferation and increase apoptosis with potentially deleterious effects (45). In 
addition, corticosteroids have negative effects on vascular function by reducing 
prostaglandin E (PGE) production by vascular smooth muscle cells, enhancing 
vasoconstriction in response to angiotensin II and reducing vasodilation in response to 
arachidonic acid (46). The mineralocorticoid aldosterone has been shown to decrease 
endothelial cell nitric oxide (NO) production through inactivation of endothelin-B 
receptor (47) with resulting adverse effect on vascular tone. Cotricosteroids have a 
degree of mineralocorticoid activity in addition to their glucocorticoid effects and 
therefore may also have this effect. All of the mechanisms described above have the 
potential to reduce any benefit brought about by the anti-inflammatory properties of 
corticosteroids. Indeed, hyperoxia induced lung injury has been shown to be worsened 
by administration of corticosteroids (48). It is therefore important not to dismiss 
inflammation when considering the pathophysiology of IPF but to acknowledge that its 
role in the emerging picture of epithelial/endothelial injury with aberrant wound 
healing remains poorly understood.     
The final common pathway in IPF is believed to be the accumulation and activation of 
fibroblasts and myofibroblasts with resulting extracellular matrix deposition and 
fibrosis. The origin of fibroblasts in IPF has been the subject of recent research with the 
discovery of epithelial-mesenchymal transformation (EMT) and the fibrocyte (cells of 
bone marrow origin that migrate to the lung prior to differentiating into fibroblasts 
and myofibroblasts) (37).  
Chilosi et al. first suggested the process of EMT in IPF in 2003 (49). EMT is the process 
by which epithelial cells transform into mesenchymal cells through a series of events 
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including loss of epithelial polarity, detachment from the basement membrane and 
alteration of cytoskeletal architecture in response to a series of intra and extra cellular 
events (50). Initiation of EMT is dependent on the interaction between extracellular 
signals including collagen and hyaluronic acid in the extracellular matrix and soluble 
growth factors including TGF-β (50). The result is a loss of expression of the key 
epithelial markers and the adoption of mesenchymal cell markers (table 2).  
Epithelial Markers Mesenchymal Markers 
E-cadherin 
Claudins 
Occludins 
Desmoplakin 
Cytokeratin-8,-9 and -18 
Mucin-1 
Fibronectin 
Vitronectin 
FSP-1 
Vimentin 
Smooth-muscle actin 
FGFR2 IIIb and IIIc splice 
variants 
Table 2. Cell markers characteristic of epithelial and mesenchymal cells(50) 
Several in vitro and in vivo studies have confirmed that type-II pneumocytes undergo 
EMT in response to TGF- 1 as evidenced by reduced expression of epithelial 
phenotype markers, increased expression of mesenchymal phenotype markers and 
increased collagen production (51-54). The epithelial integrin α3β1 has been 
implicated in this process through its role in the phosphorylation of β-catenin to form 
pY654-β-catenin/pSmad2 complex resulting in initiation of EMT in response to TGF-β1 
(55). In bleomycin induced pulmonary fibrosis, α3 integrin knockout mice failed to 
produce the pY654-β-catenin/pSmad2 complex and despite exhibiting a normal 
inflammatory response did not go on to develop fibrosis (55). This process appears to 
be relevant to IPF with lung tissue from IPF patients demonstrating pY654-β-
catenin/pSmad2 complexes not present in control samples (55). 
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The role of EMT in experimental models of lung fibrosis is well established and the 
underlying mechanism and its role in IPF remains the subject of research.  
Fibrocytes were first described in 1994 as a circulating cell that was morphologically 
distinct from leukocytes and had characteristics similar to fibroblasts (56). They have a 
unique phenotype expressing collagen, vimentin and CD34 (56). These cells express a 
number of chemotaxin receptors including CCR7 and CXCR4, undergoing chemotaxis in 
response to secondary lymphoid chemokine and CXCL12 respectively and have been 
demonstrated to localise to the lungs with associated increased collagen deposition in 
a mouse model of bleomycin induced pulmonary fibrosis (57;58). Elevated CXCL12 has 
been demonstrated in patients with IPF compared to controls with a negative 
correlation between CXCL12 levels and carbon monoxide diffusion capacity of the lung 
(59). There is evidence to suggest that in the mouse model, inhibition of the CXCR4 
receptor reduced circulating fibrocyte numbers with a reduction in lung collagen 
deposition (60). These bone marrow-derived mesenchymal progenitor cells therefore 
represent an interesting new development in IPF research and indeed there is a 
suggestion that the presence of increased number of circulating fibrocytes in IPF 
patients is a marker of poor prognosis with raised mortality (61). However, the 
fibrocyte is not without controversy and there remains valid concern regarding the 
robustness of the methodology used in their identification and it has been suggested 
that rather than representing a unique population of cells (fibrocytes) they represent a 
range of different leukocytes(62). Further research to clarify the existence of the 
fibrocyte is required with subsequent investigation into the mechanisms underlying 
their recruitment and transmigration if their existence is confirmed.  
Il-1  is a proinflammatory cytokine implicated in many diseases. Kolb et al (43) 
investigated its role in tissue fibrosis using adenoviral gene transfer resulting in 
transient over expression in rat lungs. A vigorous acute inflammatory response was 
demonstrated with elevation of the profibrotic cytokines PDGF and TGF-  in BAL fluid. 
Although the acute inflammatory response resolved over 2 weeks, TGF-  remained 
elevated at 60 days. Associated progressive tissue fibrosis with histological 
confirmation of myofibroblasts and fibroblastic foci was seen (43). The role of Il-1  in 
pulmonary fibrosis is supported by evidence that patients with a polymorphism in the 
Il-1 receptor antagonist gene are at increased risk of developing the disease (63). Il-1  
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activates a series of cell adhesion molecules resulting in leukocyte transmigration in 
response to endothelial activation (64).  
Despite ongoing investigation of the origin of fibroblasts in IPF their role is not 
debated. The same is true for the role of TGF-β despite ongoing research clarifying the 
specific mechanisms behind its involvement. As previously mentioned, a current 
hypothesis for IPF is based upon initial injury with altered healing mechanisms leading 
to the pathological features of the disease. The source of this initial injury is not yet 
known and may indeed not be consistent. However, it is generally suggested that 
alveolar epithelial injury is the initial event. This is supported by the development of 
pulmonary fibrosis following type II alveolar cell injury in a mouse model (65). 
Alternatively, it is important to consider the possibility that the primary injury or 
pathology may be endothelial. Indeed the pathological picture of UIP is recognised in 
response to both inhaled environmental factors (asbestosis) and circulating factors 
(connective tissue disease). A study of 40 patients with IPF revealed significantly 
elevated factor VIII levels (a marker of endothelial cell injury) in IPF patients versus 
controls. These patients were also noted to have positive antiphospholipid antibodies 
in 37/40 compared to 6/26 in the control group (66). Immunofluorescence and light 
microscopy of lung biopsies in these patients revealed evidence of immunoglobulin 
and complement deposition in the interalveolar septae and appearances consistent 
with immune-mediated microvascular injury (66). A similar study by Matsui et al. (67) 
assessed the presence of anti-endothelial cell antibodies by enzyme-linked 
immunosorbent assay (ELISA) using human umbilical vein endothelial cells (HUVEC) in 
the sera of patients with IIP. This study failed to demonstrate anti-endothelial cell 
antibodies in patients with IPF however did identify them in patients with NSIP and UIP 
related to connective tissue diseases (67). These findings do not appear to have been 
investigated elsewhere in the literature but these studies do highlight the need to 
consider the importance of the endothelium in the pathogenesis of IPF and its 
interplay with other circulating cells and molecules.  
The existing hypotheses regarding the pathogenesis of IPF are broad and have so far 
failed to identify a novel pathogenic process or prompt the development of a disease 
modifying therapy. Furthermore, much of the evidence underlying current concepts in 
IPF stem from the bleomycin mouse model of pulmonary fibrosis and therefore have 
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questionable applicability to IPF. It is therefore essential to consider new hypotheses 
and explore existing hypotheses with greater focus.  
The endothelium provides a constant barrier between the circulation and the lung 
interstitium trafficking circulating cells through the lung. Endothelial cell activation can 
lead to leukocyte transmigration and resulting inflammatory response. Another 
circulating cell with significant effects on the lung is platelets. The relationship 
between platelets and the lung is complex with important physiological functions and 
association with pathology (68).  Platelets have been implicated in lung diseases 
including cystic fibrosis (69), asthma, pulmonary hypertension and adult respiratory 
distress syndrome / acute lung injury. (68) The role of platelets in IPF is not however 
clearly defined.  
1.5 Platelets and the Lung 
Platelets have a diameter of approximately 2-4 m and survive in the circulation for 
approximately 7-9 days. They are formed from the cytoplasm of megakaryocytes that 
circulate in the blood originally forming long processes termed proplatelets that 
branch during maturation forming platelets at the tip with subsequent release (70). 
The lung appears to play an important role in this process with megakaryocytes and 
proplatelets entering and fragmenting in the pulmonary circulation to produce 2 or 
more platelets resulting in higher platelet numbers being recorded in the pulmonary 
venous circulation versus the pulmonary arterial system (71). Using electron 
microscopy, megakaryocytes have been demonstrated in the pulmonary capillaries of 
mice at various stages of platelet release following stimulation of thrombopoesis 
through venesection or administration of thrombopoetin (72). 
Platelets are anucleate but maintain other cellular cytoplasmic organelles (73). Within 
the platelet cytoplasm there are several different granules, namely, alpha granules, 
dense granules and lysosomes that contain a wide range of proinflammatory, 
profibrotic and prothrombotic factors (70;74). The alpha granules contain numerous 
adhesion molecules necessary for platelet, leukocyte and endothelial interactions in 
addition to containing mitogenic factors including PDGF (75) and TGF-  (76); 
coagulation factors; and protease inhibitors(77). The activation of platelets results in 
the release of the contents of alpha granules and dense granules through exocytosis 
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(77;78). In addition, platelets synthesise IL-1β via a regulated post-transcriptional 
pathway that can be released in microvesicles or into solution with resulting 
endothelial cell activation, cell adhesion molecule expression and chemokine 
production culminating in neutrophil accumulation and activation (79). Following 
activation, platelets continue to circulate and have been shown to have the same 
lifespan as non-activated platelets (80). Although the surface P-selectin is cleaved 
within a matter of hours with release of a soluble form into the plasma (80;81), the 
platelet remains functional for a prolonged period with potential to contribute to 
inflammatory and thrombotic states (79).    
A process similar to leukocyte adhesion and transmigration takes place allowing 
platelets to adhere to the intact endothelium. The first step in this process is mediated 
by P-selectin, a member of the selectin family of cell adhesion molecules that is found 
in the alpha granules of platelets and the Weibel-Palade bodies of endothelial cells 
(82;83). Through Ca2+ dependent translocation P-selectin becomes rapidly expressed 
on the surface of endothelial cells where it facilitates the rolling of platelets on the 
endothelial surface (84). Subsequent firm adhesion is mediated by the 3 integrins, 
glycoprotein IIb/IIIa (GPIIb/IIIa) and v 3. Intercellular adhesion molecule-1 (ICAM-1) 
has also been implicated in this process (85). Through complex intracellular signalling 
processes the activated, endothelial bound platelets can release potent inflammatory 
and pro-fibrotic mediators (73).  
In addition to the lungs’ role in platelet production from proplatelets, the pulmonary 
microvasculature appears to act as a sieve removing platelets and other circulating 
cells from the circulation. A study using radiolabeled platelets demonstrated that one 
third of platelets are extracted on a single pass through healthy rabbit lungs although 
they remain in the lung for less than ten minutes (86). This leads to the question 
whether platelet sequestration in the lungs through cell adhesion molecule 
interactions and resultant release of inflammatory and pro-fibrotic mediators plays a 
role in chronic fibrotic lung diseases, namely IPF. Platelet trapping in the lung has been 
demonstrated using indium-111 labelled platelets in response to intravenous 
bleomycin with an association between platelet trapping and collagen deposition (87). 
Interestingly, in this study, treatment with antiCD11a monoclonal antibody 
significantly reduced the number of platelets in contact with the alveolar endothelium 
 27 
suggesting involvement of the 2-Integrins in this process. This is further supported by 
evidence of platelet sequestration in the lung following hyperoxia induced lung injury. 
On this occasion, treatment with anti-TNF-  resulted in reduced platelet surface 
CD11a expression and resulting reduced pulmonary sequestration (88). It is therefore 
reasonable to hypothesise that platelet sequestration in the lungs as a result of cell 
adhesion molecule interactions and associated platelet activation would result in a 
local release of known pro-fibrotic mediators.  
As previously discussed, there is an increased incidence of cardiovascular and venous 
thromboembolic events in patients with IPF (3;4). Atherosclerosis underlies the 
development of cardiovascular disease with development of an atherosclerotic plaque 
leading to coronary artery luminal narrowing with flow limitation on exertion resulting 
in clinical symptoms of angina. Disruption of an atherosclerotic plaque exposes the 
subendothelial matrix leading to platelet thrombus formation with profound luminal 
narrowing or obstruction resulting in an acute coronary syndrome. Atherosclerosis 
involves both inflammation (89) and thrombosis (90). These two processes appear to 
play a role in IPF, although this has not yet been fully defined.  In light of the important 
relationship between platelets and the lungs it is important to consider the 
relationship between platelets and IPF and the association between IPF and vascular 
events.  Platelet activation and interaction with inflammatory cells is increased in 
patients with stable coronary artery disease as demonstrated by increased percentage 
of circulating platelet-monocyte complexes and increased platelet expression of P-
selectin (91).  
The alpha granules of platelets contain platelet endothelial cell adhesion molecule-1 
(PECAM-1)/CD31), a complex molecule found on platelets, leukocytes and endothelial 
cells with many important functions (92). Therefore, in addition to the direct effect of 
proinflammatory and fibrotic mediators on the lung, the release of PECAM-1 may have 
additional consequences. PECAM-1 plays an important role in leukocyte transmigration 
in coordination with other cell adhesion molecules.  
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1.6 PECAM-1 
 PECAM-1 is a 130 kDa glycoprotein that belongs to the Immunoglobulin superfamily. It 
is coded for by a single copy gene consisting of 65kb divided into 16 exons on 
chromosome 17 (93). It consists of 6 extracellular domains each coded for by a 
separate exon (exons 3-8), a transmembrane portion coded on exon 9 and a complex 
intracytoplasmic tail with immunoreceptor tyrosine-based inhibitory motif (ITIM) 
domains coded for by 7 different exons (exons 10-16) (93). PECAM-1 is expressed on 
platelets, leukocytes and endothelial cells (92) and its mRNA is highly expressed in the 
lung, heart, kidneys, brain and liver (94;95).  
A soluble form of PECAM-1 exists as a 100 kDa molecule that is missing the 
transmembrane and intracytoplasmic components. This soluble form is thought to 
result from membrane shedding and through alternative mRNA splicing (96). 
Numerous variants have been described with alternative splicing including a soluble 
PECAM-1 molecule with deletion of exon 9 (94). The process of shedding from 
endothelial cells is dependent on the matrix metalloproteinases and is thought to 
occur in the early stages of cell apoptosis. The complete PECAM-1 molecule appears to 
protect against apoptosis while the truncated form appears to have a role in the 
completion of apoptosis (97;98). An alternative source of soluble PECAM-1 production 
is via cleavage from platelets when exposed to high shear stress. This process has been 
demonstrated by observing reduced PECAM-1 expression on the surface of platelets 
exposed to high shear stress and was found to be dependent on the activation of 
calpain and the glycoprotein Ib (GPIb) – von Willebrand Factor (vWF) interaction (99). 
PECAM-1 is a complex molecule with diverse functions, possibly dependent on its form 
and a complex process of cell signalling and phosphorylation of the intracytoplasmic 
domains. Indeed, where full length PECAM-1 is known to play an important role in 
leukocyte transmigration, addition of soluble PECAM-1 blocks this process (100). The 
role of PECAM-1 in leukocyte transmigration is attributed to its 1st extracellular domain 
(coded on exon 3) that is felt to mediate homophilic interactions necessary for this 
process (93). Using a monoclonal antibody to PECAM-1 or recombinant soluble 
PECAM-1, monocyte and neutrophil transmigration can be reduced by 70-90% (100). A 
number of heterophilic PECAM-1 ligands have also been identified although the 
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function of their interaction with PECAM-1 is not understood. Examples of proposed 
heterophilic PECAM-1 ligands include αvβ3 integrin (101), CD38  (102) and CD177 (103) 
and are felt to interact predominantly with the 2nd extracellular domain coded on exon 
4 of the gene. 
In addition to leukocyte transmigration numerous other functions have been 
attributed to PECAM-1 (see Figure 1) including: angiogenesis; mechanosensing and 
response in vascular stretch (104); regulation of platelet collagen interactions and 
platelet signalling pathways limiting growth of platelet thrombi (105); regulation of 
macrophage phagocytosis preventing the engulfing of healthy cells; and clearance of 
apoptotic cells(94;106). 
The role of PECAM-1 has been investigated in a number of different diseases. A 
number of single nucleotide polymorphisms (SNP’s) including Leu125Val on exon 3, 
Ser563Asn on exon 8 and Gly670Arg on exon 12 of the PECAM-1 gene have been 
associated with coronary artery disease with variable results (107-110). The Gly670Arg 
SNP on exon 12 has been shown to have a functional impact on molecular function in 
an ex vivo study demonstrating increased adhesion and transmigration of monocytes 
with a Gly/Gly genotype compared with an Arg/Arg genotype (111). The three 
described SNP’s demonstrated strong linkage disequilibrium (107) and therefore the 
phenotypic  difference resulting from the exon 12 SNP is also likely to be observed in 
association with SNP’s in exon 3 and 8.   
Elevated soluble PECAM-1 levels have been observed in stable coronary artery disease 
and during acute myocardial infarction reinforcing the association of this molecule 
with vascular events (109;112). A similar association has been observed in ischaemic 
stroke (113). 
Expression of PECAM-1 has also been observed in many endothelial and 
haemotopoetic malignancies with over expression being related to resistance to 
chemotherapy induced apoptosis (114). As a result PECAM-1 is being investigated as a 
possible target for anti-cancer drugs. The role of PECAM-1 has not been investigated in 
fibrotic pulmonary disease.   
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Figure 1. PECAM-1 consists of 6 extracellular domains coded on exons 3-8, a 
transmembrane portion coded on exon 9 and a complex intracytoplasmic tail with 
immunoreceptor tyrosine-based inhibitory motif (ITIM) domains coded on exons 10-
16.  
Interestingly, in PECAM-1 deficient mice, an idiopathic fibrotic pulmonary pathology 
has been identified. In this study of two strains of PECAM-1 deficient mice (FVB -/- and 
C57BL/6 -/- strains) the FVB -/- group were noted to develop respiratory distress with 
subsequent mortality (106). The most common abnormality identified in the lungs of 
these mice was diffuse alveolar damage with interstitial thickening and in many cases 
type II pneumocyte hyperplasia, increased numbers of alveolar macrophages and 
fibrosis with collagen deposition. This disease process was seen in the FVB -/- mice but 
not in the C57BL/6 -/- mice strain. This suggests that the latter strain may have 
PECAM-1 independent pathways that protect against the deleterious effects of 
PECAM-1 deficiency observed in the FVB -/- strain. Indeed, this mouse strain also has a 
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lesser reduction in acute inflammatory response associated with PECAM-1 deficiency 
than the other mouse strain (106).  
When considering the possible role of PECAM-1 in IPF it is noteworthy that PECAM-1 
has been demonstrated to be involved in the transmigration of CD34 positive 
haematopoietic progenitor cells through the endothelium into bone marrow following 
haematopoietic stem cell transplantation (115). In this study, immortalized primary 
endothelial cells pre-treated and activated with Il-1β were used to assess the 
transmigration of CD34 positive haematopoietic stem cells in response to the 
chemokine stem cell derived factor-1 (SDF-1). Reduction of transendothelial migration 
was observed with the addition of PECAM-1 blocking antibody with additional 
reduction with blockade of Beta1 and Beta2 integrin function demonstrating their 
involvement in this process (115). This raises the question whether bone marrow 
derived CD34 positive fibrocytes also undergo PECAM-1 dependent transmigration in 
the lung in patients with IPF. There has been little investigation of PECAM-1 expression 
on circulating fibrocytes. In a model of ischaemia/reperfusion cardiomyopathy cardiac 
fibroblasts were studied after 5 days of ischaemia/reperfusion injury demonstrating a 
significant proportion expressing CD34 and CD45 with a smaller spindle shaped 
morphology (116). These cells did not express PECAM-1 (CD31) at this stage expressing 
alpha-smooth muscle actin, collagen I and vimentin (116). The question remains 
however whether circulating fibrocytes may express PECAM-1 with loss of expression 
associated with development into active fibroblasts and myofibroblasts.  
1.7 Haemostasis and IPF 
Haemostatic mechanisms in health maintain vascular integrity preventing 
haemorrhage while maintaining vascular patency by preventing inappropriate 
thrombosis. There is a complex interplay between haemostatic processes, 
inflammation and cellular/tissue injury resulting in disordered haemostatic processes 
being implicated in the pathogenesis of many diseases. There are three main 
mechanisms by which haemostasis is maintained: primary haemostasis involves the 
formation of a platelet plug; secondary haemostasis involves formation of a fibrin clot 
through activation of the coagulation cascade; and fibrinolysis promotes the 
destruction of fibrin clot in order to maintain vascular patency and maintain 
haemostatic homeostasis. Platelets are central to primary haemostasis and have been 
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discussed in a previous section and therefore this section will focus on the role of 
secondary haemostasis and fibrinolysis in IPF. 
Secondary Haemostasis: Formation of the Fibrin Clot 
Secondary haemostasis can be activated through intrinsic or extrinsic pathways, the 
latter requiring the interaction of tissue factor (TF) with factors VII and VIIa. TF is a 
43kD transmembrane cell surface glycoprotein that interacts with factor VII and VIIa to 
form a complex that in turn activates factor X with resulting production of thrombin 
from prothrombin that in turn converts fibrinogen to fibrin. This process is inhibited by 
tissue factor pathway inhibitor (TFPI) that forms a complex with factor Xa prior to 
inhibiting the action of TF/factor VIIa complex (117).  
Local activation of the coagulation cascade has been demonstrated as a key process in 
IPF. TF and TFPI have been demonstrated to be increased in BAL samples from patients 
with IPF with higher levels seen in those with advanced disease (117;118). Despite 
elevated levels of TFPI corresponding with increased TF expression there was a positive 
correlation with a procoagulant state suggesting the procoagulant effects of TF 
outweighed the anticoagulant effects of TFPI (117). Hyperplastic type II pneumocytes, 
epithelial cells lining fibroblastic foci and macrophages have been demonstrated to 
express TF with associated fibrin deposition in the lungs of patients with IPF and not in 
healthy lungs (117;119). A similar pattern was seen in patients with scleroderma 
related interstitial lung disease and BOOP (119). The occurrence of this process across 
different diseases suggests that this is a response to lung injury rather than a primary 
event.   
Fibrinolysis 
Fibrinolysis is an essential process in maintaining haemostatic homeostasis preventing 
excess accumulation of fibrin clot and resulting tissue and organ dysfunction. The 
interplay between factors promoting and inhibiting this process has been 
demonstrated to be important in lung injury and lung fibrosis. Plasmin is central to the 
process of fibrinolysis but is a broad-spectrum protease enzyme capable of breaking 
down many other extracellular proteins in addition to fibrin. It is therefore believed to 
play an important role in repair following alveolar injury (120). Plasmin is produced 
from plasminogen in response to plasminogen activator. The alveolar space in health 
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favours fibrinolysis due to local abundance of urokinase-type plasminogen activator (u-
PA) however plasminogen activator inhibitors (PAI) have been demonstrated to be 
increased in cases of acute lung injury including adult respiratory distress syndrome 
leading to persistence of intra alveolar extracellular matrix proteins (121). There are 
two identified PAI but the most important implicated in this process is PAI-type 1 (PAI-
1) (121).  
PAI-1 is a member of the serpine superfamily and is the main inhibitor of u-PA and 
tissue-type plasminogen activator (t-PA). It acts by forming a stable 1:1 serine-
proteinase/serpine complex. PAI-1 has been investigated in a mouse model of 
pulmonary fibrosis induced by intratracheal administration of bleomycin using 
genetically modified mice with up regulated PAI-1 expression (PAI +/+) and down 
regulated PAI expression (PAI -/-). PAI-1 deficient mice (PAI-/-) were found to be 
relatively protected from the fibrogenic effects of intratracheal bleomycin with 
markedly lower collagen deposition measured by lung tissue hydroxyprolene content 
than PAI+/+ mice. There appeared to be a correlation between gene expression and 
collagen deposition with heterozygous mice (PAI +/-) having an intermediate fibrotic 
response to intratracheal bleomycin (120). This finding demonstrates the importance 
of impaired plasmin production through excessive plasminogen inhibition via PAI-1 in 
the fibrotic response to lung injury in a mouse model. Intra-nasal administration of 
small interfering RNA has been utilised to reduce PAI-1 levels in the lungs of mice with 
resulting attenuation of the fibrotic process following intratracheal bleomycin 
representing a promising therapeutic option (122). PAI-1 has also been implicated in 
human disease. A study of bronchoalveolar lavage (BAL) specimens from patients with 
IPF found significantly elevated levels of PAI-1 and PAI-type 2 (PAI-2) in IPF patients 
compared with controls.  There was no difference in u-PA or t-PA levels in BAL in these 
patients suggesting a shift in balance from pro-fibrinolytic to anti-fibrinolytic in 
patients with IPF (118). In IPF, PAI-1 has a similar pattern of expression to TF being 
localised to hyperplastic type-2 pneumocytes, macrophages and the columnar 
epithelium lining areas of honeycomb fibrosis (122). Investigation of the prevalence of 
polymorphisms in the promoter region of the PAI-1 gene in IIP’s failed to demonstrate 
a significant difference however subgroup analysis revealed an association with NSIP 
but not UIP (123).  
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PAI-1 has been associated with cardiovascular disease with increased plasma activity 
observed following acute myocardial infarction (124). Increased PAI-1 production has 
been demonstrated in response to platelet associated growth factors including 
epidermal growth factor (EGF) and TGF-β and directly in response to platelet lysates ex 
vivo in cultured human hepatocytes (125) and in vivo in a rabbit model (126). This 
demonstrates that platelet factors known to be released with platelet activation can 
promote PAI-1 production with resulting inhibition of plasmin production leading to 
accumulation of fibrin and extracellular matrix proteins as observed in IPF.  Despite 
high TGF-β concentrations in the lung following intravenous administration there was 
no associated increase in lung PAI-1 mRNA expression with increases limited to the 
aorta, heart and liver leading the authors to suggest that endothelial cells and 
hepatocytes are predominantly responsible for the increased plasma levels (126). 
Given the increased PAI-1 production by hyperplastic type II pneumocytes in patients 
with IPF it is conceivable that platelet factors could play a role in this process and 
therefore warrants further investigation.  
In addition to promoting PAI-1 production by other cells, platelets retain PAI-1 mRNA 
and continue to produce the active molecule (127). This represents an alternative 
source of PAI-1 that warrants further investigation in patients with IPF.     
IPF and Anticoagulation 
Kubo et al. (128) performed a randomised controlled trial of anticoagulation in 
addition to steroid therapy in patients with IPF in order to identify the presence of a 
coagulation disorder in IPF and assess the effect of anticoagulation with warfarin on 
survival. Sixty-four patients were recruited to the study with 56 patients completing 
the study (33 in the non-anticoagulant group and 23 in the anticoagulant group). It is 
noteworthy that all patients dropping out of the study were in the anticoagulant group 
with 6 fearing side effects of treatment or frequent venepuncture, 1 experiencing 
purpura and 1 moving away from the locality. Plasma D-Dimer levels on recruitment to 
the study were elevated in both groups increasing further during acute exacerbations 
of the disease.  
D-Dimer is a fibrin degradation product and is released into the plasma following 
endogenous fibrinolysis. It therefore represents increased activation of haemostatic 
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mechanisms and is used clinically in risk stratification in the diagnosis of venous 
thromboembolic disease but is elevated in a wide range of conditions including but not 
limited to sepsis, trauma, vascular disease and malignancy. The elevated D-Dimer level 
at baseline in IPF patients suggests background activation of haemostatic mechanisms. 
Patients were randomised to receive prednisolone alone or prednisolone and 
anticoagulation with outpatient warfarin (target international normalised ratio (INR) of 
2.0-3.0) and intravenous low molecular weight heparin during admission with acute 
exacerbations. The mortality rate was significantly lower in the anticoagulant group 
with 5/23 deaths during the study period compared with 20/33 deaths in the non-
anticoagulant group (p=0.006) with 1-year survival rates of 87% and 58% respectively. 
The reduced mortality was associated with a significant reduction in d-dimer in the 
anticoagulant group. Despite the small number of patients included in the study, the 
lack of blinding and results reported only for those actually receiving the intervention 
and not on an intention to treat basis these results appeared promising and supported 
an important role for coagulation/haemostatic mechanisms in disease progression.  
Noth et al. did not support these findings in a later study (23) that randomised patients 
with progressive IPF to warfarin (target INR 2.0-3.0) or placebo for a 48-week 
treatment period. This study was stopped early after a mean follow-up period of 28 
weeks due to increased mortality in the warfarin group (14/72 in the warfarin group 
and 3/73 in the placebo group). The trial evidence regarding warfarin is therefore 
inconsistent but the robust methodology in the later study by Noth et al. compared 
with the original smaller, open label study by Kubo et al. strongly suggests an absence 
of benefit with warfarin therapy and indeed probable harm. Despite this, it is clear that 
there is an imbalance within the lungs of IPF patients that favours fibrin and 
extracellular matrix deposition and inhibition of fibrinolysis.  
The finding of Kubo et al. (128) that D-Dimer levels were elevated at baseline and 
increased during an acute exacerbation supports the importance of haemostatic 
mechanisms in IPF. D-Dimer directly reflects fibrinolysis and we know from studies of 
PAI-1 in BAL specimens that fibrinolysis is suppressed in the alveoli of patients with IPF. 
As previously discussed, studies have identified localised release of prothrombotic 
mediators including TF in areas of pulmonary fibrosis with increased inhibition of 
fibrinolysis mediated by PAI-1. However, studies have demonstrated that IPF is 
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associated with venous thromboembolic disease and cardiovascular disease 
supporting a systemic prothrombotic tendency. The origin of elevated fibrin 
degradation products in the circulation of patients with IPF is therefore unclear but has 
two potential sources: firstly it may originate from the lungs where there is an 
imbalance between fibrin deposition and fibrinolysis resulting in net fibrin deposition 
and accumulation of extracellular matrix proteins in the alveolar spaces; or secondly, it 
may represent a systemic activation of haemostatic mechanisms with increased fibrin 
deposition and fibrinolysis with localised lung disease due to local imbalance favouring 
fibrin and extracellular matrix deposition due to PAI-1 release from hyperplastic type II 
pneumocytes and macrophages.  
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2. PECAM-1 and Idiopathic Pulmonary Fibrosis 
 
2.1 Introduction 
PECAM-1 is a complex molecule with a diverse range of functions including leukocyte 
transmigration, angiogenesis, vascular mechanosensing, platelet adhesion and 
apoptosis. A strain of PECAM-1 knockout mice spontaneously developed pulmonary 
fibrosis similar to IPF raising the possibility of a role for this molecule in IPF 
pathogenesis (106). The role of PECAM-1 in IPF has not previously been investigated. 
Interestingly, soluble PECAM-1 has been demonstrated to be elevated in 
cardiovascular disease (112) and a number of studies have demonstrated an 
association between the recognised PECAM-1 SNP’s and cardiovascular disease. In 
light of the increased incidence of cardiovascular disease in IPF (3) it is important to 
consider whether a common PECAM-1 genotype may provide an explanation for this 
link.  
There are 3 recognised SNP’s within the PECAM-1 gene: Leu125Val in exon 3, 
Ser563Asn in exon 8 and Gly670Arg in exon 12. Importantly, an ex vivo study of the 
Gly670Arg polymorphism in exon 12 demonstrated a phenotypic difference between 
Gly homozygous and Arg homozygous HUVEC. HUVEC that were Gly homozygous 
demonstrated significantly increased PECAM-1 tyrosine phosphorylation and 
monocyte adhesion and transmigration compared with Arg homozygous cells (111). 
The three PECAM-1 SNP’s have been demonstrated to exhibit strong linkage 
disequilibrium and therefore Gly homozygosity in exon 12 implies association with 
complementary polymorphisms in exon 3 and 8. These findings support a functional 
impact of PECAM-1 SNP’s leading to the question whether variation in polymorphism 
frequency predisposes to the development of IPF.  
Soluble PECAM-1 (sPECAM-1) can arise from membrane shedding or alternate mRNA 
splicing with deletion of exon 9. It has been observed to be elevated in cardiovascular 
and cerebrovascular disease (112;113); however, its role and origin in vascular disease 
is unknown. The role of sPECAM-1 in IPF has not previously been investigated.  
In order to investigate the role of PECAM-1 in IPF we assessed the frequency of the 
recognised SNP’s in exon 3 (Leu125Val), exon 8 (Ser563Asn) and exon 12 (Gly670Arg) 
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of the PECAM-1 gene. We also measured the plasma concentration sPECAM-1 and 
correlated this with lung function measurements.  
2.2 Method 
Patient Selection 
IPF patients diagnosed according to ATS/ERS criteria were recruited from the local 
interstitial lung disease clinic in a large teaching hospital. All patients entering the 
study were stable at the time of sampling being clinically free from infection or acute 
exacerbation. Control patients with non-fibrotic respiratory conditions were recruited 
from both outpatient and in-patient clinical settings. Control patients were clinically 
well at the time of sampling and free of clinical signs of infection. Those recruited from 
in-patient settings were awaiting discharge following resolution of the medical 
complaint leading to admission and were assessed to ensure that there was no 
evidence of ongoing infection or inflammation. A total of 37 IPF patients and 41 
controls entered the study. A random selection of these patients went on to have the 
sPECAM-1 concentration measured (IPF n=20, Controls n=17). Lung function 
measurements were available for 15 of the IPF patients undergoing sPECAM-1 
measurement. The regional ethics committee approved the study and written 
informed consent was obtained from all participants.  
PECAM-1 Single Nucleotide Polymorphisms 
From each of the 37 IPF patients and 41 controls entering the study, samples of whole 
blood were collected and anticoagulated with Ethylenediaminetetraacetic acid (EDTA). 
The whole blood was stored at -80oC prior to thawing for DNA extraction using QIAmp 
DNA Blood Midi Kit (Qiagen, Valencia, CA). The extracted DNA was stored at -20oC 
prior to being thawed and PCR performed using primers specific for exon 3, exon 8 and 
exon 12 of the PECAM-1 gene (table 3). The following PCR protocol was used: 95oC for 
2 minutes followed by 30 cycles of 95oC for 30 seconds, 55oC for 30 seconds and 72oC 
for 45 seconds prior to a final step of 72oC for 10 minutes on completion of cycling. The 
PCR product was then purified using Nucleospin Extract II PCR Clean-up and gel 
extraction kit (Machary-Nagel, Düren, Germany) and a selection analysed using gel 
electrophoresis to confirm the presence of a product of correct size. Sequencing was 
undertaken by Eurofins MWG Operon.  
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Soluble PECAM-1 
A random selection of the original cohort (IPF n=20, Controls n=17) had additional 
blood collected and anticoagulated with lithium heparin. The samples were 
centrifuged at 1,500G for 10 minutes at 20oC and the plasma collected. sPECAM-1 
concentration was measured using eBioscience Human sPECAM-1 instant ELISA 
(eBioscience, San Diego, USA). Lung function measurements were available for 15 of 
the IPF patients. For the purposes of assessing the effect of sPECAM-1 on lung function 
IPF patients were divided into two groups using an arbitrary TLCO cut off (TLCO >50% 
predicted and TLCO≤50% predicted) and analysis performed using an unpaired t-test. 
Data Analysis 
This study had 80% power to detect a difference in allele frequency of 30% with a p-
value of <0.05 considered significant.  Allele frequencies were analysed using 2x2 
contingency tables and Fishers Exact test. The mean sPECAM-1 concentrations were 
analysed using an unpaired t-test.  
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Exon 3 
 Sequence (5'->3') 
Strand on  
template 
Length Start Stop Tm GC% 
Forward 
primer 
TCACCGGGATGATGTTGTTTCTGA
G 
Plus 25 1 25 57.06 48.0% 
Reverse 
primer 
TGCTCCATCTGCTTGCCGTGC Minus 22 397 376 59.9 59.1% 
        
Product 
length 
397  
 
Exon 8 
  Sequence (5'->3') 
Strand on  
template 
Length Start Stop Tm GC% 
Forward 
primer 
CTGGTTTTCAGCCCCGGTGGA Plus 21 511 531 58.96 61.9% 
Reverse 
primer 
ACACTGGAGGCGTGGTTGGC Minus 20 900 881 59.55 65.0% 
Product 
length 
390   
 
Exon 12 
  Sequence (5'->3') 
Strand on  
template 
Length Start Stop Tm GC% 
Forward 
primer 
GGACCCAGGACCCAGAGACAGT
G 
Plus 23 206 228 59.93 65.2% 
Reverse 
primer 
GCATCTCTGGTGAAAGCAGCTAG
C 
Minus 24 575 552 58.15 54.2% 
Product 
length 
370   
 
Table 3. PCR primers for exon 3, exon 8 and exon 12 of the human PECAM-1 gene. 
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2.3 Results 
IPF patients were older than controls (p=0.01) and there was an increased prevalence 
of COPD in the control group (p=0.001). Otherwise, the groups were well matched for 
all variables and all participants were Caucasian (table 4). There was no significant 
difference in allele frequency for the SNP’s on exon 3 (p=0.33), exon 8 (p=0.33) or exon 
12 (p=0.30) of the PECAM-1 gene (table 5). 
 IPF Controls P-value 
Number (n) 
Age in years – Mean (SD) 
Gender (%) 
- Male 
- Female 
Comorbidities (%) 
- IHD 
- TIA/CVA 
- PVD 
- Hypertension 
- Diabetes mellitus 
- Hypercholesterolaemia 
- COPD 
- Asthma 
- Sleep apnoea 
- DVT/PE 
Smoking Status (%) 
- Current 
- Ex-smoker 
- Non-smoker 
- Unknown 
FVC – Mean % predicted (SD)* 
TLCO – Mean % predicted (SD)* 
37 
74.1 (7.67) 
 
26 (70.3) 
11 (29.7) 
 
11 (29.7)                                                                                                                                                                                                                                                                                                                                  
4 (10.8) 
3 (8.1) 
10 (27.0) 
3 (8.1) 
2 (5.4) 
3 (8.1) 
0 (0) 
0 (0) 
2 (5.4) 
 
4 (10.8) 
18 (48.7) 
3 (8.1) 
12 (32.4) 
100.1 (17.5) 
53.8 (12.0) 
41 
66.1 (15.45) 
 
22 (53.7) 
19 (46.3) 
 
8 (19.5)
3 (7.3) 
1 (2.4) 
5 (12.2) 
8 (19.5) 
3 (7.3) 
24 (58.6) 
2 (4.9) 
1 (2.4) 
3 (7.3) 
 
8 (19.5) 
16 (39.0) 
5 (12.2) 
12 (29.3) 
- 
- 
 
0.01 
 
0.16 
0.16 
 
0.42
0.69 
0.34 
0.15 
0.20 
1.00 
0.001 
0.49 
1.00 
1.00 
 
0.35 
0.49 
0.71 
0.81 
 
Table 4. Baseline characteristics of patients with IPF and controls. 
 *Lung function data for the IPF patients undergoing sPECAM-1 measurement for whom lung function data was available (n=15) 
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SNP Exon Genotype  IPF 
n=37 
Controls 
n=41 
p Value 
 
Leu125Val 
 
 
Ser563Asn 
 
 
Gly670Arg 
 
3 
 
 
8 
 
 
12 
 
 
C / No C 
G / No G 
 
G / No G 
A / No A 
 
G / No G 
A / No A 
 
28 / 9 
29 / 8 
 
28 / 9 
26 / 11 
 
27 / 10 
30 / 7 
 
26 / 15 
32 / 9 
 
26 / 15 
 33 / 8 
 
31 / 10 
28 / 13 
 
0.33 
1.00 
 
0.33 
0.43 
 
0.80 
0.30 
Table 5. The prevalence of single nucleotide polymorphisms in exon 3, exon 8 and 
exon 12 of the PECAM-1 Gene  
 
IPF and control patients within the subgroup of participants undergoing analysis of 
soluble PECAM-1 concentration were well matched with no significant age difference 
(p=0.06). Soluble PECAM-1 was significantly higher in the IPF group versus controls 
(106.18ng/ml versus 84.33ng/ml respectively) p=0.04 (figure 2).  
The mean sPECAM-1 concentration was 130.38ng/ml in the TLCO>50% predicted 
group versus 86.78ng/ml in the TLCO≤50% predicted group (p=0.04) (figures 3 and 4) 
 
   
Figure 2. Soluble PECAM-1 concentration in IPF (n=20) versus Controls (n=17) 
(p=0.04) 
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Figure 3. Soluble PECAM-1 concentration in IPF patients with TLCO >50% predicted 
versus IPF patients with TLCO ≤50% predicted (p=0.04) (n=15) 
 
Figure 4. Correlation between soluble PECAM-1 concentration and TLCO (R2=0.16, 
p=0.14) 
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2.4 Discussion 
This study does not demonstrate any significant difference in SNP frequency between 
IPF patients and controls. Although this study was underpowered to detect small 
differences in genotype we suggest that if a PECAM-1 polymorphism was clinically 
significant it would be evident in the vast majority of IPF patients. We therefore 
conclude that there is no clinically significant difference in SNP frequency between the 
groups.  
The mean age in the IPF group was older than the mean age in the control group. It 
could be argued that participants in the control group may later go on to develop IPF, 
however, the low incidence of IPF in the general population makes it very unlikely that 
this would have a significant impact on the results. It is important to note that there 
was no significant age difference between IPF patients and controls in the subgroup 
undergoing analysis of sPECAM-1. The increased prevalence of COPD in the control 
group reflects the method of recruitment of control subjects from respiratory 
outpatient clinics and inpatients awaiting discharge. 
It is noteworthy that there appears to be geographical variation in the prevalence of 
PECAM-1 polymorphisms with genotypes varying significantly between Slovenian and 
Indian populations in two separate studies of the Leu125Val SNP on exon 3 in 
cardiovascular disease (109;129). The genotype frequencies (CC/CG/GG) in the control 
groups of the Slovenian and Indian studies were 17.1%/53.5%/29.4% and 
42.7%/47.3%/10% respectively. In these studies, cardiovascular disease was found to 
be associated with the C allele in a Slovenian population and the G allele in an Indian 
population (109;129). Conclusions must therefore be drawn with care with the 
appreciation that a lack of association in this white British population cannot be 
generalised to other patient populations.   
sPECAM-1 can result from membrane shedding of the extracellular component or 
through alternate mRNA splicing with loss of the transmembrane portion coded on 
exon 9 and therefore consisting of the extracellular component and intracytoplasmic 
tail. The individual roles of these distinct forms of sPECAM-1 have not been 
established. We demonstrate an increased plasma concentration of sPECAM-1 in IPF 
compared with controls with higher levels associated with preserved lung function. 
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However, the nature of the increased sPECAM-1 and its functional implications have 
not been established. A potential mechanism for preserved lung function associated 
with higher sPECAM-1 is through blockade of homophilic interaction of membrane 
bound forms of the molecule by occupying the binding sites. Goldberger et al. (96) 
demonstrated that sPECAM-1 at a concentration of 10μg/ml resulted in almost 
complete blockade of membrane bound PECAM-1 interactions with lower 
concentrations resulting in partial blockade. It is however important to note that the 
concentrations studied in this experiment are significantly greater than the plasma 
concentrations observed in this study.  
2.5 Conclusion 
Despite the spontaneous development of pulmonary fibrosis in PECAM-1 knockout 
mice there was no clinically significant difference in PECAM-1 polymorphism frequency 
in IPF patients and controls in the studied population. However, the plasma 
concentration of sPECAM-1 was significantly higher in the IPF group compared with 
controls with higher concentrations associated with preserved lung function. The 
origin and functional impact of the observed elevation of sPECAM-1 in IPF requires 
further investigation.    
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3. Platelet Reactivity in Idiopathic Pulmonary Fibrosis 
 
3.1 Assessment of Markers of Platelet Activation in Idiopathic Pulmonary Fibrosis 
and Controls at Basal Levels and Following Agonist Induced Platelet Activation 
 
3.1.1 Introduction 
Platelets are anucleate cells that survive in the circulation for 7-9 days and have 
important roles in haemostasis, wound healing and inflammation. Platelets are 
recognised to be closely linked with the lungs in health and in disease. In physiology, 
platelets are produced from megakaryocytes and proplatelets within the pulmonary 
circulation (71). However, a number of respiratory diseases have been associated with 
platelets in animal and human models. 
Platelet trapping in the lung has been demonstrated following intravenous bleomycin 
and is strongly correlated with collagen deposition (87). Seven days following 
bleomycin administration, increased platelet adherence to the pulmonary 
endothelium was observed using electron microscopy. These changes persisted for 
approximately three weeks.  Platelet adhesion to the endothelium in this model is 
believed to be mediated by CD11a as addition of a blocking monoclonal antibody 
largely reversed this process (87). Platelets have also been implicated in human lung 
diseases including adult respiratory distress syndrome (68) and cystic fibrosis (69;130). 
Patients with cystic fibrosis have been demonstrated to have increased platelet 
activation in basal conditions and increased platelet reactivity in the presence of a 
platelet agonist. This was found to be secondary to plasma factors and intrinsic platelet 
mechanisms and was demonstrated by increased levels of circulating platelet-
leukocyte complexes and increased platelet surface P-selectin expression (130). 
Similarly, studies of patients with ARDS have revealed markers of increased platelet 
activation, platelet sequestration within the lung and microthrombi within alveolar 
capillaries (68;131). This recognised association with respiratory disease including 
animal models of pulmonary fibrosis led us to question the role of platelets in IPF. 
There is a recognised association between vascular disease and IPF with an increased 
incidence of cardiovascular disease and venous thromboembolism (3;4). Increased 
platelet activation and reactivity is recognised in both stable coronary artery disease 
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and acute coronary syndromes (91). We hypothesise that platelet activation and 
reactivity will be increased in patients with IPF with implications for its pathogenesis 
and providing a link with cardiovascular disease. 
3.1.2 Method 
Patient Selection 
Patients with IPF diagnosed in accordance with ATS/ERS criteria (9) were recruited 
from the interstitial lung disease clinic at a large University Hospital. All patients were 
stable at the time of sampling being free from infection and/or disease exacerbation. 
Age and sex matched controls without interstitial lung disease were selected from out-
patient clinics within the same hospital and stable inpatients awaiting discharge. A 
total of 13 IPF patients and 12 controls were recruited into the study. Basic 
demographic information was collected in addition to details of comorbidities, 
antiplatelet drug use, smoking status and lung function data when available (table 6). 
For the purposes of this study current smokers were classified as those who smoked in 
the preceding six months prior to sampling, ex-smokers as those who had stopped 
smoking prior to six months before the study and non-smokers as those who had 
never smoked. In light of the well-recognized increased platelet-monocyte binding and 
platelet activation in ischaemic heart disease (91), patients with a known history of 
ischaemic heart disease were not eligible for inclusion in this study. The local ethics 
committee approved the study and written informed consent was obtained from all 
participants.  
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Demographic IPF (%) Controls (%) p-value 
Number 
Age (mean) 
      <50 
     51-60 
     61-70 
     71-80 
     >80 
Gender 
     Male 
     Female 
Comorbidities 
     COPD 
    Prev. Malignancy 
     Hypertension 
     Diabetes mellitus 
     TIA 
    CVA 
     Atrial Fibrillation 
Anti-platelet drug use 
     Aspirin 
     Clopidogrel 
     Dipyridamole 
     Other 
Smoking Status 
     Non-smoker 
     Ex-smoker 
     Current Smoker 
n=13 
70.3 
0 (0) 
0 (0) 
8 (61.5) 
5 (38.5) 
0 (0) 
 
9 (69.2) 
4 (30.8) 
 
2 (15.4) 
2 (15.4) 
4 (30.8) 
0 (0) 
3 (23.1) 
0 (0) 
1 (7.7) 
 
4 (30.8) 
0 (0) 
1 (7.7) 
0 (0) 
 
1 (7.7) 
10 (77.9) 
2 (15.4) 
n=12 
66.2 
0 (0) 
4 (33.3) 
3 (25) 
4 (33.3) 
1 (8.3) 
 
8 (66.7) 
4 (33.3) 
 
6 (50) 
1 (8.3) 
1 (8.3) 
2 (16.7) 
0 (0) 
0 (0) 
2 (16.7) 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
6 (50) 
4 (33.3) 
2 (16.7) 
 
0.22 
- 
- 
- 
- 
- 
 
1.00 
1.00 
 
0.09 
1.00 
0.30 
0.22 
0.22 
1.00 
0.58 
 
0.09 
1.00 
1.00 
1.00 
 
0.03 
0.04 
1.00 
Table 6. Baseline Characteristics of IPF patients and controls following exclusions. 
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Blood Collection 
Blood was collected using a 21-gauge butterfly needle (Becton Dickinson Vacutainer 
Systems, UK) into two 4.5ml vacutainer tubes anticoagulated with 0.105 Molar Sodium 
Citrate (Becton Dickinson Vacutainer Systems, UK). The first tube was discarded in 
order to prevent inadvertent platelet activation at the time of venepuncture 
influencing the results. All samples were used within 20 minutes of venesection and 
flow cytometry performed within 2 hours. Platelet monocyte complexes and platelet 
activation were assessed using the following protocols. 
Platelet-Monocyte Complexes    
50μl of whole blood was incubated for 20 minutes in basal conditions and in the 
presence of varying concentrations of adenosine diphosphate (ADP) or the protease 
activated receptor - 1 (PAR-1) agonist TFLLR (0.1, 1 and 10μM ADP and 1, 5 and 10μM 
TFLLR) with 10μl FITC-conjugated anti CD42b (BD Biosciences, UK) and 5μl RPE-
conjugated anti CD14 (AbD Serotec, UK). Each sample was prepared in duplicate with 
the addition of 5μl of 100mM EDTA to alternate tubes in order to measure the 
presence of cation dependent platelet-monocyte binding.  Red blood cells were then 
lysed using 500μl FACS Lyse solution (BD Biosciences, UK). Samples were further 
diluted at a ratio of 1:2 with phosphate buffered saline (PBS) prior to performing two-
colour flow cytometry. Monocytes were identified by their specific forward and side 
scatter properties and confirmed by positive CD14 binding (figure 5). The percentage 
of monocytes (CD14+) forming platelet-monocyte complexes (CD14+, CD42b+) was 
calculated. Statistical significance was assessed using an unpaired t-test with a p value 
of <0.05 considered significant.  
Markers of Platelet Activation  
5μl of whole blood was incubated for 20 minutes in basal conditions and in the 
presence of ADP or TFLLR of varying concentrations (0.1, 1 and 10μM ADP and 1, 5 and 
10μM TFLLR) with PE-conjugated anti-human CD62P (Biolegend, San Diego, California) 
or FITC-conjugated anti-fibrinogen antibodies (Dako, UK). A separate sample was 
incubated with FITC-conjugated CD42b to confirm that the gated population was 
platelets. The samples were made up to 50μl with PBS. Following incubation samples 
were fixed with 500μl of 1% paraformaldehyde prior to flow cytometry. Data was 
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expressed as the percentage of platelets expressing CD62p and fibrinogen (figure 6).  
Statistical significance was assessed using an unpaired t-test with a p value of <0.05 
considered significant. 
Flow Cytometry 
Flow cytometry was performed using a Becton Dickinson FACS Calibur flow cytometer 
(Becton Dickinson, UK). Data were analyses using CellQuest Pro software (Becton 
Dickinson, UK).  
 
Figure 5. A. Scatter plot demonstrating whole blood flow cytometry gated on 
monocytes. B. Quadrant plot demonstrating CD14 positive cells (monocytes) in the 
upper two quadrants (FL2 high) and CD42b positive cells (platelets) in the right two 
quadrants (FL1 high) with platelet-monocyte complexes (FL2 high and FL1 high) in 
the right upper quadrant.  
 
 
Figure 6. A. Scatter plot demonstrating whole blood flow cytometry using platelet 
settings gated on platelets. B-E Histograms demonstrating resting platelets with low 
P-selectin and fibrinogen expression (B and D respectively) and activated platelets 
with significantly increased P-selectin expression and fibrinogen binding (C and E 
respectively).  
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3.1.3 Results 
Platelet-Monocyte Complexes 
There were a greater percentage of platelet-monocyte complexes in the IPF group 
compared with controls reaching statistical significance at higher levels of stimulation. 
The percentage of monocytes forming platelet complexes in IPF and controls were 
18.2% and 13.7% at basal levels (p=0.302), 24.1% and 15.3% with 0.1μM ADP 
(p=0.097), 29.4% and 16.1% with 1μM ADP (p=0.007), and 44.8% and 32.1% with 
10μM ADP (p=0.014). A similar trend was observed with platelet stimulation by TFLLR 
with platelet-monocyte complexes in IPF and controls of 28.6% and 18.6% with 1μM 
TFLLR (p=0.06), 41.7% and 27% with 5μM TFLLR (p=0.002), and 61% and 41.1% with 
10μM TFLLR (p=0.001) respectively. The percentage of platelet-monocyte complexes is 
demonstrated in table 7 and figure 7. The addition of EDTA resulted in a significant 
decrease in percentage of platelet-monocyte complexes. In the presence of EDTA 
there was no difference in proportion of platelet monocyte complexes between groups 
or with addition of platelet agonist (Figure 8). 
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         Percentage of Platelet-Monocyte 
Complexes (SD) 
 
Platelet Agonist IPF (n=13) Controls (n=12)  p-value 
Basal 
 
0.1μM ADP 
1μM ADP 
10μM ADP 
 
1μM TFLLR 
5μM TFLLR 
10μM TFLLR 
18.19 (13.99) 
 
24.08 (16.87) 
29.40 (14.85) 
44.83 (11.81) 
 
28.59 (16.38) 
41.73 (8.92) 
61.05 (14.16) 
13.71 (4.68) 
 
15.28 (5.16) 
16.10 (5.25) 
32.11 (12.09) 
 
18.65 (6.19) 
27.03 (11.93) 
41.09 (12.14) 
0.30 
 
0.09 
<0.01 
0.01 
 
0.06 
<0.01 
<0.01 
Table 7. Platelet-monocyte complex formation in basal and stimulated conditions.  
 
 
Figure 7. Percentage of monocytes forming complexes with platelets in basal 
conditions and when stimulated with 0.1μM ADP, 1μM ADP, 10μM ADP, 1μM TFLLR, 
5μM TFLLR and 10μM TFLLR in IPF and controls. # p=0.01, * p=<0.01 
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Figure 8. Percentage of monocytes forming complexes with platelets in the presence 
of 10mM EDTA in basal conditions (p=0.33) and when stimulated with 0.1μM ADP 
(p=0.17), 1μM ADP (p=0.25), 10μM ADP (p=0.14), 1μM TFLLR (p=0.57), 5μM TFLLR 
(p=0.93) and 10μM TFLLR (p=0.95) in IPF and controls. 
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Markers of Platelet Activation 
In basal conditions there was no significant increase in platelet expression of P-selectin 
or fibrinogen in IPF patients compared to controls (0.99% versus 0.70%, p=0.25 and 
19.92% versus 8.67%, p=0.13 respectively). However, with increasing stimulation the 
difference in P-selectin expression becomes significant as demonstrated in table 8 and 
figure 9. The difference in fibrinogen expression when stimulated with ADP reaches 
statistical significance at moderate levels losing significance as both groups reach 
maximal stimulation. A similar trend was observed with TFLLR however it failed to 
reach statistical significance. Fibrinogen expression in the two groups is demonstrated 
in table 9 and figure 10.   
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         Percentage of platelets positive for  
P-selectin (SD) 
 
Platelet Agonist IPF (n=13) Controls (n=12)  p-value 
Basal 
 
0.1μM ADP 
1μM ADP 
10μM ADP 
 
1μM TFLLR 
5μM TFLLR 
10μM TFLLR 
0.99 (0.52) 
 
1.86 (1.65) 
9.78 (4.52) 
41.27 (15.16) 
 
3.05 (5.99) 
16.81 (19.06) 
51.53 (33.32) 
0.70 (0.64) 
 
0.72 (0.44) 
3.25 (2.66) 
22.52 (9.15) 
 
0.99 (0.87) 
5.28 (7.13) 
23.10 (18.98) 
0.25 
 
0.03 
<0.01 
<0.01 
 
0.25 
0.06 
0.02 
Table 9. Platelet expression of P-selectin in basal and stimulated conditions.  
 
Figure 9. Platelet expression of P-selectin in basal conditions and when stimulated 
with 0.1μM ADP, 1μM ADP, 10μM ADP, 1μM TFLLR, 5μM TFLLR and 10μM TFLLR in 
IPF and controls. * p=<0.01 ** p=<0.05 
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         Percentage of platelets positive for 
fibrinogen (SD) 
 
Platelet Agonist IPF (n=13) Controls (n=12)  p-value 
Basal 
 
0.1μM ADP 
1μM ADP 
10μM ADP 
 
1μM TFLLR 
5μM TFLLR 
10μM TFLLR 
19.92 (21.49) 
 
50.28 (31.91) 
77.92 (16.70) 
92.13 (6.09) 
 
49.30 (32.23) 
68.49 (27.81) 
83.10 (19.09) 
8.67 (11.05) 
 
17.48 (21.23) 
56.24 (22.62) 
86.36 (8.81) 
 
31.82 (24.23) 
46.61 (26.34) 
71.78 (21.65) 
0.13 
 
<0.01 
<0.01 
0.07 
 
0.15 
0.06 
0.18 
Table 9. Platelet expression of fibrinogen in basal and stimulated conditions.  
 
 
Figure 10. Platelet expression of fibrinogen in basal conditions and when stimulated 
with 0.1μM ADP, 1μM ADP, 10μM ADP, 1μM TFLLR, 5μM TFLLR and 10μM TFLLR in 
IPF and controls. * p=<0.01 
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3.1.4 Discussion  
This study demonstrates significantly increased platelet reactivity in IPF patients 
compared to controls as demonstrated by a concentration dependent increase in 
platelet-monocyte complex formation, platelet P-selectin expression and platelet 
fibrinogen binding in the presence of` the platelet agonists ADP and TFLLR. The 
reproducibility using two different platelet agonists demonstrates that this is not 
restricted to a single pathway of activation. The addition of EDTA returned platelet-
monocyte complex formation to basal levels with no difference between IPF patients 
and controls confirming that this interaction is divalent cation dependent consistent 
with P-selectin mediated adhesion.  
At basal levels there was a trend to increased platelet activation that was reproducible 
across the measured activation markers however this did not reach statistical 
significance. Due to the small sample size and the inter-individual variability this study 
was underpowered to detect a difference at basal levels however the use of citrate 
anticoagulation during sample preparation may have contributed. 
It is recognised that the choice of anticoagulant used in sample preparation can affect 
platelet-monocyte binding. Although there is no consensus on the best anticoagulant 
to use for this purpose it is important to recognise the influence that the anticoagulant 
can have on the result. Heparin based anticoagulants are known to cause platelet 
activation by binding to the integrin αIIbβ3 (GPIIb/IIIa) resulting in an enhanced 
response to platelet agonists (132). The use of heparin anticoagulation therefore has 
the potential to overestimate platelet activation by spuriously increasing platelet 
monocyte complex formation, platelet P-selectin expression and platelet fibrinogen 
binding. Conversely, anticoagulation with citrate results in a degree of calcium 
chelation. The interaction between platelet P-selectin and P-selectin glycoprotein 
ligand-1 (PSGL-1) expressed on monocytes is divalent cation dependent and therefore 
citrate anticoagulation causes platelet-monocyte complex formation to be spuriously 
low (133). In order to prevent a potential false positive result due to the use of heparin 
anticoagulation we chose to use citrate anticoagulation. This may have reduced our 
capability to identify a difference at basal levels. Despite this, this study clearly 
demonstrates increased platelet activation in a concentration dependent manner that 
is reproducible across the three markers of platelet activation and two pathways of 
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activation. This provides compelling evidence of increased platelet reactivity in IPF and 
emphasises the importance of interactions between the lung, the vasculature and 
circulating cells. Additionally, it provides insight into the recognised link between IPF 
and vascular diseases.  
This study does not establish the causal relationship of this phenomenon. It is 
therefore not possible to conclude whether the increased platelet reactivity precedes 
the development of pulmonary fibrosis and therefore is important in the pathogenesis 
of the condition or whether it is a secondary effect of the pulmonary fibrotic process. 
However, it is recognised that the increased incidence of cardiovascular and venous 
thromboembolic disease in IPF patients precedes the diagnosis of their lung disease 
(3;4). It could therefore be postulated that patients with IPF have a prothrombotic 
tendency that predates their lung disease and that this may be associated with the 
increased platelet reactivity demonstrated in this study. Although this is by no means 
confirmed by this observation there is little doubt that activated platelets have the 
potential to drive fibrosis.  
During platelet activation they degranulate releasing numerous profibrotic cytokines 
including TGF-β (76) and PDGF (75) that are recognised to be important in the 
pathogenesis of IPF. Abnormal platelet activation has been demonstrated in 
connective tissue disease related interstitial lung disease adding further support to a 
possible pathogenic role. Interstitial lung disease secondary to scleroderma has been 
shown to be associated with increased platelet activation demonstrated by elevated 
plasma platelet factor 4 (PF4) levels, not observed in scleroderma patients without 
interstitial lung disease (134). It is therefore plausible that the observed increased 
platelet reactivity in IPF contributes to the fibrotic process through local activation and 
degranulation with release of proinflammatory and profibrotic mediators within the 
pulmonary circulation.  
The two groups in this study were well matched with equal sex distribution and similar 
age. However, although not statistically significant, there was a higher prevalence of 
cerebrovascular disease in the IPF group with 3 patients having suffered a TIA in the 
past. There is a recognised association between cerebrovascular disease and platelet 
activation (135), however repeat analysis of the data with exclusion of patients with 
cerebrovascular disease did not alter the results and therefore they have been 
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included in the final analysis. The increased use of antiplatelet drugs in the IPF group 
reflects the inclusion of patients with cerebrovascular disease. The platelet assays used 
in this study are not affected by the specific antiplatelet medications being used by the 
patients in the IPF group.   
There is a similar distribution of cardiovascular risk factors between the two groups. 
However, a greater proportion of the IPF group were ex-smokers as would be expected 
with the disease being more prevalent in this group. The four current smokers in this 
study were all still smoking at the time of sampling and were evenly distributed 
between both groups meaning that the recognised increased platelet activation and 
surface expression of P-selectin in smokers (136) will not have affected the results in 
this study.  
Following completion of this study a report was published suggesting that 
prednisolone has the potential to reduce platelet activation when added to whole 
blood following venepuncture (137). This was only observed in response to ADP and 
not other platelet agonists and following addition of prednisolone and not other 
corticosteroids. In order to ensure that this did not influence our findings, a 
retrospective review of corticosteroid use was performed. Two subjects were taking 
low-dose maintenance prednisolone in this study (1 in the IPF group and 1 in the 
control group). A further 2 patients in the control group had been treated for an acute 
exacerbation of COPD within the preceding 2 weeks and therefore are likely to have  
received high-dose corticosteroids as part of their treatment. Reanalysis of the data 
excluding these patients did not alter the results (data not shown) and therefore they 
were included in the final analysis.  
Patients with COPD have recently been demonstrated to have increased levels of 
circulating platelet-monocyte complexes compared to age and smoking status 
matched controls with a further increase observed during an acute exacerbation (138). 
In the exacerbating group, blood was sampled during the acute hospitalisation and 
therefore these patients are likely to have been receiving oral prednisolone as part of 
their treatment. The increased platelet-monocyte complex formation in this group 
does not support any significant effect of prednisolone on platelet activation in 
patients. Furthermore, the high prevalence of COPD in the control group in this study 
may result in the difference between the groups being underestimated. This adds 
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further support to the significance of the observed increased platelet reactivity in 
patients with IPF.   
3.1.5 Conclusion 
The results of this study demonstrate increased platelet reactivity in patients with IPF 
compared to age and sex matched non-interstitial lung disease controls.  This 
demonstration of an abnormal platelet response in IPF patients provides insight into 
the link between IPF and vascular disease and the need for further investigation of the 
role of the vasculature in IPF. This study does not establish cause and effect and 
further investigation is required to better understand the mechanism underlying the 
observed increased platelet reactivity and the functional consequences.  
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3.2 The Effect of Plasma on Platelet Activation in Idiopathic Pulmonary Fibrosis 
3.2.1 Introduction 
Patients with IPF demonstrate increased platelet reactivity compared with age and sex 
matched non-interstitial lung disease controls as demonstrated in the previous 
experiment. It is important to establish whether this is due to an intrinsic platelet 
defect that predisposes patients to develop fibrotic disease or whether the increased 
reactivity is due to an external plasma factor that primes an otherwise normal platelet 
for activation. In order to assess this, a plasma swap approach was used.  
3.2.2 Method 
Blood collection 
Venous blood was collected using a 21-gauge butterfly needle (Becton Dickinson 
Vacutainer Systems, UK) from 7 control patients without evidence of interstitial lung 
disease, other fibrotic condition or cardiovascular disease. The first 6mls of blood was 
collected into a vacutainer tube anticoagulated with 102 IU lithium heparin (Becton 
Dickinson Vacutainer Systems, UK) and was used for isolation of patient plasma. 
Plasma was stored at -80oC and thawed at room temperature prior to use. Subsequent 
blood was collected in four 4.5ml vacutainer tubes anticoagulated with 0.105 Molar 
Sodium Citrate (Becton Dickinson Vacutainer Systems, UK) and used for isolation of 
platelets.  
Blood was collected in the same way from 7 patients with IPF diagnosed in accordance 
with the ATS/ERS criteria that were clinically stable at the time of sampling and free 
from any acute intercurrent illness. Blood collected into a vacutainer tube 
anticoagulated with 102 IU lithium heparin (Becton Dickinson Vacutainer Systems, UK) 
was used for isolation of patient plasma. Plasma was stored at -80oC and thawed at 
room temperature prior to use.  
Preparation of Washed Platelets 
Citrate anticoagulated blood was centrifuged at 900 rpm for 20 minutes at 20oC to 
produce platelet rich plasma (PRP). 0.3M citric acid was added to the PRP to achieve a 
PH of 6.4 in order to prevent platelet activation during the washing process. The PRP 
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was further centrifuged at 1,900 rpm for 12 minutes at 20oC to produce a platelet 
pellet and the supernatant was discarded. The platelet pellet was suspended in wash 
buffer (PH 6.5) by gentle pipetting prior to a final centrifugation at 2,200 rpm for 10 
minutes at 20oC. The supernatant was discarded and the washed platelet pellet was 
suspended in 300μl PBS. The washed platelets were used immediately following 
preparation.  
Isolation of Plasma 
Lithium heparin anticoagulated blood was centrifuged at 1,500G for 10 minutes at 
20oC and the plasma supernatant was collected. The plasma was separated into 100μl 
aliquots and stored at -80oC until needed. The plasma was thawed and incubated at 
room temperature prior to further centrifugation at 13,000rpm for 2 minutes to 
ensure any cellular debris was removed.  
Plasma swap Protocol  
Washed platelets suspended in PBS were separated into three 100μl aliquots. 100μl of 
autologous plasma was added to the first aliquot of washed platelets, 100μl of plasma 
from a control patient was added to the second aliquot and 100μl of plasma from an 
IPF patient was added to the final aliquot resulting in 3 suspensions of washed 
platelets constituting an Autologous Control, an Allogeneic Control and an IPF sample 
(see Figure 11). 5μl of each sample was individually incubated for 20 minutes in basal 
conditions and in the presence of ADP (0.1, 1 and 10μM) with PE-conjugated anti-
human CD62P (Biolegend, San Diego, California) and separately with FITC-conjugated 
anti-fibrinogen antibodies (Dako, UK). A separate sample was incubated with FITC-
conjugated CD42b to confirm that the gated population was platelets. The samples 
were made up to 50μl with PBS. Following incubation samples were fixed with 500μl of 
1% paraformaldehyde prior to flow cytometry. Data were expressed as the percentage 
of platelets expressing P-selectin or fibrinogen in the three groups and as the 
difference in expression of P-selectin/fibrinogen binding compared with the 
autologous control.  Statistical significance was assessed using a paired t-test with a p 
value of <0.05 considered significant.  
Flow cytometry was performed using a Becton Dickinson FACS Calibur flow cytometer 
and data were analysed using CellQuest Pro software (Becton Dickinson, UK). 
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Figure 11. Illustration of procedure for the preparation of washed platelets and the 
plasma swap protocol.  
3.2.3 Results 
Platelet P-selectin expression was significantly greater following incubation in IPF 
plasma compared with platelets incubated in autologous control and allogeneic 
control plasma at basal levels and following stimulation with ADP at concentrations of 
0.1 and 1 μM. Following stimulation with 10μM ADP there was no significant 
difference between the groups as maximal stimulation was reached (figure 12 – 16). 
Further analysis of the data was performed to compare the change in platelet P-
selectin expression in the Allogeneic Control and IPF groups from baseline taken as the 
platelet P-selectin expression in the Autologous Control group. The change in platelet 
P-selectin expression in the IPF group was significantly greater than the Control group 
at basal level and following stimulation with all concentrations of ADP (figure 17). 
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Figure 12. Platelet P-selectin expression following incubation in autologous plasma 
(Autologous Control), control patient plasma (Allogeneic Control) and IPF patient 
plasma (IPF) in basal conditions and following stimulation with ADP (0.1, 1 and 
10μM). Data expressed as percentage of platelets positive for P-selectin ± SEM. 
(n=7). * P= <0.05, # P= ≤0.01, NS = no significant difference. 
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IPF 
 
Controls 
 
P-value 
Number (n) 
Age in years – Mean (SD) 
Gender (%) 
- Male 
- Female 
Comorbidities (%) 
- IHD 
- TIA/CVA 
- Hypertension 
- Diabetes mellitus 
- GER 
- COPD 
- Sleep apnoea 
Smoking Status (%) 
- Current 
- Ex-smoker 
- Non-smoker 
- Unknown 
7 
74 (8) 
 
6 
1 
 
1 
1 
1 
1 
2 
0 
0 
 
0 
4 
2 
1 
7 
65 (10) 
 
4 
3 
 
0 
0 
2 
0 
2 
2 
2 
 
0 
4 
2 
1 
 
0.07 
 
0.56 
0.56 
 
1.00 
1.00 
1.00 
1.00 
1.00 
0.46 
0.46 
 
1.00 
1.00 
1.00 
1.00 
Table 10. Baseline characteristics for IPF and control groups in plasma swap 
experiment.  
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Figure 13. Dot plot demonstrating platelet P-selectin expression following incubation 
with autologous plasma (Autologous Control), control patient plasma (Allogeneic 
Control) and IPF patient plasma (IPF) at basal levels. The mean P-selectin expression 
was 7.56 ± 1.69% in the Autologous Control group, 7.54 ± 1.72% in the Allogeneic 
Control group and 14.78 ± 2.44% in the IPF group. The platelet P-selectin expression 
in the IPF group was significantly greater than in the Autologous Control group 
(p=<0.05) and the Allogeneic Control group (p=<0.05). There was no significant 
difference between the Autologous Control and Allogeneic Control groups (p=0.86). 
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Figure 14. Dot plot demonstrating platelet P-selectin expression following 
stimulation with 0.1μM ADP and incubation with autologous plasma (Autologous 
Control), control patient plasma (Allogeneic Control) and IPF patient plasma (IPF). 
The mean P-selectin expression was 9.29 ± 1.86% in the Autologous Control group, 
9.78 ± 1.84% in the Allogeneic Control group and 17.04 ± 2.04% in the IPF group. The 
platelet P-selectin expression in the IPF group was significantly greater than in the 
Autologous Control group (p=0.01) and the Allogeneic Control group (p=0.005). There 
was no significant difference between the Autologous and Allogeneic Control groups 
(p=0.33). 
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Figure 15. Dot plot demonstrating platelet P-selectin expression following 
stimulation with 1μM ADP and incubation with autologous plasma (Autologous 
Control), control patient plasma (Allogeneic Control) and IPF patient plasma (IPF). 
The mean P-selectin expression was 22.1 ± 3.11 % in the Autologous Control group, 
23.64 ± 3.54% in the Allogeneic Control group and 33.51 ± 2.39% in the IPF group. 
The platelet P-selectin expression in the IPF group was significantly greater than in 
the Autologous Control group (p=0.001) and the Allogeneic Control group (p=0.004). 
There was no significant difference between the Autologous and Allogeneic Control 
groups (p=0.4). 
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Figure 16. Dot plot demonstrating platelet P-selectin expression following 
stimulation with 10μM ADP and incubation with autologous plasma (Autologous 
Control), control patient plasma (Allogeneic Control) and IPF patient plasma (IPF). 
The mean P-selectin expression was 62.36 ± 4.38% in the Autologous Control group, 
62.09 ± 4.82% in the Allogeneic Control group and 64.39 ± 4.76% in the IPF group. 
There was no significant difference between platelet P-selectin expression in the IPF 
group compared with the Autologous Control group (p=0.23) and the Allogeneic 
Control group (p=0.06). There was no significant difference between the Autologous 
and Allogeneic Control groups (p=0.88). 
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Figure 17. Change in platelet P-selectin expression from the Autologous Control 
following incubation with Allogeneic Control plasma and IPF plasma. Data expressed 
as percentage of platelets positive for P-selectin ± SEM. * P=<0.05, # P=≤0.01. 
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There was no significant difference in fibrinogen binding between the three groups 
(figure 18-22). The difference in platelet fibrinogen binding reached statistical 
significance between the Allogeneic Control and IPF groups following stimulation with 
1μM ADP with greater binding in the Allogeneic Control group. However, there was no 
statistically significant difference between either of these groups and the Autologous 
Control group. The same findings are true when the data is analysed to compare the 
change in fibrinogen binding in the Allogeneic Control and IPF groups from baseline 
taken as the fibrinogen binding in the Autologous Control group (figure 23).  
 
  
Figure 18. Platelet fibrinogen binding following incubation in autologous plasma 
(Autologous Control), control patient plasma (Allogeneic Control) and IPF patient 
plasma (IPF) in basal conditions and following stimulation with ADP (0.1, 1 and 
10μM). Data expressed as percentage of platelets positive for fibrinogen ± SEM. # 
P=≤0.01. Unless stated otherwise there was no statistically significant difference 
noted between the groups.   
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Figure 19. Dot plot demonstrating platelet fibrinogen binding following incubation 
with autologous plasma (Autologous Control), control patient plasma (Allogeneic 
Control) and IPF patient plasma (IPF) at basal levels. 
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Figure 20. Dot plot demonstrating platelet fibrinogen binding following stimulation 
with 0.1μM ADP and incubation with autologous plasma (Autologous Control), 
control patient plasma (Allogeneic Control) and IPF patient plasma (IPF). 
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Figure 21. Dot plot demonstrating platelet fibrinogen binding following stimulation 
with 1μM ADP and incubation with autologous plasma (Autologous Control), control 
patient plasma (Allogeneic Control) and IPF patient plasma (IPF). 
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Figure 22. Dot plot demonstrating platelet fibrinogen binding following stimulation 
with 10μM ADP and incubation with autologous plasma (Autologous Control), 
control patient plasma (Allogeneic Control) and IPF patient plasma (IPF). 
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Figure 23. Change in platelet fibrinogen binding from the Autologous Control 
following incubation with Allogeneic Control plasma and IPF plasma. Data expressed 
as percentage of platelets positive for fibrinogen ± SEM. # P=≤0.01. Unless stated 
otherwise there was no statistically significant difference noted between the groups.   
3.2.4 Discussion 
Platelet activation measured by P-selectin expression was significantly greater 
following incubation in IPF plasma compared with autologous and allogeneic control 
plasma at basal levels and following stimulation with 0.1μM and 1μM ADP. Following 
stimulation with 10μM ADP there was no significant difference in P-selectin expression 
between the groups however the change in P-selectin expression compared with the 
autologous control was significantly greater following incubation in IPF plasma 
compared with allogeneic control plasma. This finding indicates the presence of a 
factor in IPF patient plasma resulting in increased platelet activation at basal levels and 
in response to platelet agonists.  
Fibrinogen binding was not significantly different between autologous controls, 
allogeneic controls or IPF patients at basal levels or in response to stimulation with 
ADP. There was marked variability between control samples in this assay and 
maximum stimulation was achieved in some samples following stimulation with 0.1μM 
ADP making it difficult to assess the validity of these results.  
-30 
-25 
-20 
-15 
-10 
-5 
0 
5 
10 
15 
20 
Basal 0.1 ADP 1 ADP 10 ADP 
C
h
an
ge
 in
 f
ib
ri
n
o
ge
n
 b
in
d
in
g 
fr
o
m
 
A
u
to
lo
go
u
s 
C
o
n
tr
o
l (
%
) 
Concentration of ADP (μM) 
Allogeneic Control 
IPF 
# 
 77 
The allogeneic control and IPF groups were well matched across all variables. Although 
the IPF group were slightly older than the allogeneic control group the difference was 
not statistically significant. Although it could be argued that this may still be clinically 
significant we did not identify any evidence that older age was associated with 
increased platelet activation in this patient cohort.  
Platelet P-selectin expression was significantly increased at basal levels following 
incubation in IPF plasma compared with incubation in allogeneic plasma. However, 
platelet P-selectin expression in all groups was higher than observed in the initial assay 
using whole blood flow cytometry. It is likely that the process of preparing washed 
platelets resulted in a degree of platelet activation and resulting increased P-selectin 
expression. Therefore the observed increase in the IPF group likely represents 
increased platelet reactivity as previously demonstrated.  
Although from these results it is not possible to completely exclude a co-existing 
primary platelet defect in IPF patients contributing to the increased platelet reactivity 
demonstrated in the initial whole blood assay, the demonstration that control platelets 
exhibit this same response following incubation in IPF plasma strongly indicates the 
presence of a plasma factor (soluble factor or microparticle) increasing platelet 
reactivity. Although this finding does not indicate whether this is important in the 
pathogenesis of the disease or a consequence of the fibrotic process, it further 
emphasises the important relationship between the lung and the vasculature.  
Further research is required to identify the plasma factor responsible for increased 
platelet activation and reactivity in IPF. This should include assessment of the plasma 
concentration of known platelet agonists and inhibitors. If this fails to identify a culprit, 
serum fractionation and subsequent mass spectrometry could be used to identify the 
responsible plasma protein (139).  
3.2.5 Conclusion 
Incubation of control platelets in IPF patient plasma results in increased activation 
compared to incubation in autologous and allogeneic control plasma at basal levels 
and following stimulation with ADP. This provides evidence that the increased 
reactivity observed in IPF patients is due to a plasma factor. Further research is 
required to identify the responsible plasma factor and the functional consequences. 
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4. Assessment of Platelet Function: Platelet-Endothelial Cell Adhesion 
4.1 Introduction 
Platelets can adhere to the vessel walls either via direct interaction with the 
endothelial cell or via interaction with endothelial bound leukocytes (140). Platelet-
endothelial interactions in the microvasculature have been studied most commonly in 
ischaemia-reperfusion injury however it has also been described in a wide range of 
disease states including: hypercholesterolaemia, sickle cell disease, malaria, 
endotoxemia, and experimental colitis (140). In most models the platelet adhesion to 
the vessel wall is confined to the post capillary venules although there are reports of 
adhesion to arteriole (141) and capillary (142) endothelium (140). Endothelial cell 
activation appears to play an important role in platelet endothelial interactions in the 
microcirculation (140).  
Ischaemia-reperfusion injury is the most studied model with the extent of platelet 
adhesion being dependent on the duration of ischaemia. ICAM-1 mediated endothelial 
fibrinogen deposition has been described as a prominent feature during the 
reperfusion phase of ischaemia-reperfusion injury and provides a backbone for platelet 
GPIIb/IIIa mediated firm adhesion (143;144). GPIIb/IIIa has been shown to mediate 
platelet-endothelial cell adhesion in venules in a model of ischaemia-reperfusion injury 
(141;144). This mechanism has been demonstrated by attenuation of platelet-
endothelial cell interaction following treatment with anti-fibrinogen antibodies, in 
ICAM-1 deficient mice and using platelets isolated from patients with Glanzmann 
disease (platelets deficient in GPIIb/IIIa) (141).  
P-selectin and its ligands have also been implicated in platelet rolling and firm 
adhesion to the endothelium (145-147). P-selectin is a lectin-like adhesion glycoprotein 
that in resting conditions is stored in the alpha granules of platelets and the weibel-
palade bodies of endothelial cells. On platelet activation P-selectin moves to and is 
expressed on the surface of the platelet. Likewise, during endothelial cell activation, P-
selectin becomes mobilised from the weibel-palade bodies becoming exposed on the 
cell surface.  Addition of a blocking antibody against P-selectin in a mouse model 
significantly attenuated platelet rolling and adhesion (145;146). However, it remains 
unclear to what extent this phenomenon is due to platelet P-selectin or endothelial P-
 79 
selectin. Massberg et al. reported that platelet-endothelial adhesion was not affected 
when P-selectin deficient platelets were studied with wild-type endothelium. However, 
platelet-endothelial adhesion was almost completely absent when wild-type platelets 
were assessed with P-selectin deficient endothelium (145). Cooper et al. undertook a 
similar study of platelet-endothelial adhesion in a mouse model of ischaemia-
reperfusion injury and concluded that both platelet and endothelial P-selectin play a 
role in platelet-endothelial adhesion. However, Cooper et al. described platelet P-
selectin as having a more important role (146). A study of platelet-endothelial 
interaction in rabbit lung using an ischaemia-reperfusion model confirmed increased 
platelet rolling and firm adhesion that was inhibited by blocking P-selectin interactions 
(148). Endothelial P-selectin has also been implicated in a rat model of retinal 
ischaemia with attenuation of platelet-endothelial interactions following blockade of 
endothelial P-selectin (147). Platelet PSGL-1 and GPIbα (CD42b) are important ligands 
expressed by platelets that are felt to mediate the interaction with endothelial derived 
P-selectin in venules (140). 
Different studies have demonstrated different times to peak platelet–endothelial 
interaction following reperfusion. Ischaemia-reperfusion models with rapid onset of 
platelet interaction with the vessel walls are associated with platelet-endothelial 
adhesion in arterioles and venules however models with slower onset result in 
platelet–endothelial adhesion confined to the venules (146).  
Shear forces generated by blood flow significantly affect the behaviour of circulating 
platelets and leukocytes. Laminar flow in microvessels leads red blood cells to push 
platelets and leukocytes toward the vessel wall. Low shear rates promote blood cell-
endothelial cell interactions with a reduction in shear rates resulting in an increase in 
platelet adhesion to the vessel wall (149). This effect was attenuated by blocking P-
selectin interactions but also by inducing neutropenia or blocking CD11/CD18 
demonstrating that leukocytes can form a platform for platelet-endothelial cell 
interactions (149).  
GP1bα, in addition to functioning as a ligand for endothelial derived P-selectin, has the 
ability to adhere to endothelial cells in a P-selectin independent manner at low shear 
stress via interactions with vWF expressed on the surface of activated endothelial cells 
(150;151).   
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The degree of shear force mediates the type of adhesion molecules involved in the 
adhesive process(152).  At low shear stress GPIIb/IIIa has been shown to mediate firm 
adhesion via bound fibrinogen to endothelial ICAM-1(141;153). In the setting of high 
shear stress as seen in arteries, platelet-endothelial adhesion is mediated by GPIbα 
receptors binding with matrix vWF (153;154). Platelet binding to exposed 
subendothelial matrix is mediated by GPIbα and GPIIb/IIIa binding to vWF, collagen 
and fibronectin. This process is vital in order to maintain haemostasis through 
thrombus formation; however inappropriate thrombus formation within the 
vasculature can lead to thromboemboli. 
Endothelium Intermediary Platelet 
ICAM-1 
P-selectin 
P-selectin 
vWF 
P-selectin 
ICAM-1 
 
ICAM-1 
avb3 
CD11b/CD18 
CD11b/CD18 
Fibrinogen 
- 
- 
- 
Leukocyte PSGL-1 
Leukocyte CD18 
Leukocyte PSGL-1 
Leukocyte CD11b/CD18 
- 
- 
- 
GPIIb/IIIa 
PSGL-1 
GPIbα 
GPIbα 
P-selectin 
 
P-selectin 
GPIbα 
GPIIb/IIIa 
GPIIb/IIIa 
P-selectin 
Table 11. Summary of described mechanisms of platelet-endothelial cell adhesion 
including intermediaries (152).  
Leukocytes appear to have the potential to potentiate platelet-endothelial cell 
interactions through a variety of mechanisms. Neutrophils have been demonstrated to 
contribute to the platelet-endothelial cell adhesion induced by LPS through superoxide 
production. Attenuation of platelet-endothelial interactions can be achieved by 
induction of neutropenia and blockade of neutrophil NADPH oxidase (155;156). In a 
model of experimental colitis, it was demonstrated that 97.6% of adherent platelets 
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were associated with adherent leukocytes in the inflamed colonic venules (157). 
Similarly, a model of ischaemia-reperfusion injury in small intestine demonstrated 
approximately 75% of adherent platelets being associated with adherent leukocytes 
and 25% of platelet adhering independently (156).  
Platelet adhesion to endothelial cells is influenced by chemical mediators with nitric 
oxide inhibiting the response and superoxide promoting adhesion (155;158). Both 
platelets and endothelial cells produce nitric oxide by endothelial Nitric Oxide Synthase 
(eNOS) (159;160). Nitric oxide inhibits platelet activation by increasing intracellular 
cGMP concentration ultimately leading to a reduction in intracellular calcium (159).  
Superoxide production occurs in platelets, endothelial cells and leukocytes through 
NADPH oxidase (155). Therefore, the balance between nitric oxide and superoxide in 
the microvasculature may be important in modulating platelet adhesion.  
A study of LPS induced platelet-endothelial cell adhesion in intestinal venules of mice 
demonstrated a marked increase in platelet adhesion following activation with LPS 
(161). Inhibition of endogenous nitric oxide (NO) production by L-NG-Nitroarginine 
Methyl Ester (L-NAME) resulted in a significant increase in platelet-endothelial cell 
adhesion. Conversely, the addition of the NO donor diethylenetriamine nitric oxide 
(DETA-NO) attenuated LPS induced platelet-endothelial cell adhesion through 
activation of soluble guanylyl cyclase (sGC) (161). In order to assess the source of NO 
responsible for attenuating platelet-endothelial cell interaction, eNOS deficient and 
wild-type mice were injected with eNOS deficient and wild-type platelets. Significantly 
increased platelet-endothelial adhesion was observed in eNOS deficient mice following 
treatment with LPS compared with wild-type mice however no difference was 
observed between administration of eNOS deficient platelets or wild-type platelets.   
This supports the theory that endothelial cell derived NO is responsible for attenuating 
platelet adhesion. The inhibitory effect of NO has been further investigated and 
supported by demonstrating the importance of downstream signalling molecules 
including platelet cyclic guanosine monophosphate kinase-1 (cGK-1) (143) and 
vasodilator-stimulated phosphoprotein (VASP) (162) in inhibiting platelet activation 
and platelet-endothelial cell interactions.   
As previously described, inhibition of GPIIb/IIIa is associated with reduced platelet 
adhesion to the microvasculature in a mouse model of ischaemia/reperfusion injury 
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(141). In addition, GPIIb/IIIa inhibition attenuates leukocyte recruitment to venules 
following ischaemia-reperfusion injury (163). Therefore, where some studies have 
demonstrated leukocytes to play an important role in promoting platelet-endothelial 
cell adhesion it also appears that platelets play an important role in facilitating 
leukocyte-endothelial cell interactions. Studies of ischaemia-reperfusion injury in mice 
mesentery and myocardium have shown that leukocyte-endothelial interactions were 
significantly attenuated by P-selectin and GPIIb/IIIa depletion (163;164). This effect 
could be reversed by infusion of wild-type platelets but not P-selectin deficient 
platelets suggesting that platelet P-selectin expression is central to this effect (164). In 
mouse mesentery, P-selectin expression is markedly increased following ischaemia-
reperfusion injury (163). This is attenuated by induction of thrombocytopenia or 
treatment with anti GPIIb/IIIa or fibrinogen monoclonal antibodies (163).  
Neutrophil accumulation following ischaemia-reperfusion injury measured by tissue 
myeloperoxidase activity was also attenuated by inducing thrombocytopenia or 
treatment with GPIIb/IIIa or fibrinogen monoclonal antibodies and importantly also by 
treatment with P-selectin blocking antibodies (163). This suggests that leukocyte 
adhesion to the endothelial surface in this model is facilitated by initial platelet-
endothelial cell adhesion through endothelial ICAM-1 binding fibrinogen which is 
subsequently bound by platelet GPIIb/IIIa with P-selectin dependent platelet-leukocyte 
binding.  This mechanism is further supported in a mouse model of acute 
postischaemic renal failure where neutrophil accumulation was attenuated in mice 
lacking platelet P-selectin expression but not in mice lacking endothelial P-selectin 
expression (165). 
Platelet-endothelial interactions are important in considering platelets potential 
pathogenic role in IPF. Direct interaction with the pulmonary microvascular 
endothelium resulting in platelet trapping in the lung would facilitate local release of 
profibrotic mediators during platelet activation. In addition, platelet endothelial 
interaction may facilitate the recruitment of circulating inflammatory cells with further 
increase in release of pro-inflammatory and pro-fibrotic mediators with resulting tissue 
injury and fibrosis. A simple platelet-endothelial adhesion assay was designed and 
utilised in order to identify if the observed increased platelet reactivity in IPF patients 
alters the platelet function in terms of endothelial cell interactions. This study 
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investigates platelet-endothelial cell adhesion in solution following the incubation of 
control platelets in autologous control, allogeneic control and IPF plasma.   
4.2  Method 
Platelet-endothelial cell adhesion in IPF and controls was assessed ex-vivo in 
suspension. In light of earlier findings that the increased platelet activation and 
reactivity observed in IPF patients is secondary to the effects of IPF plasma, a plasma 
swap technique was used. Control platelets suspended in plasma were added to 
HUVEC in suspension and adhesion was assessed using flow cytometry.  
Blood collection 
Venous blood was collected from an antecubital vein using a 21 gauge butterfly needle 
(Becton Dickinson Vacutainer Systems, UK). Blood samples were collected from 5 
control patients without evidence of interstitial lung disease, other fibrotic conditions 
or known vascular disease for preparation of washed platelets. Blood was collected 
from 10 clinically stable IPF patients and a further 10 control patients for preparation 
of platelet poor plasma. All IPF patients were diagnosed in accordance with ATS/ERS 
criteria and were free from any acute intercurrent illness at the time of sampling.   
Six mls of blood was taken into a vacutainer tube anticoagulated with 102 IU lithium 
heparin (Becton Dickinson Vacutainer Systems, UK) and used for preparation of 
platelet poor plasma.  
Washed platelets were prepared from blood collected in four 4.5ml vacutainer tubes 
anticoagulated with 0.105 Molar Sodium Citrate (Becton Dickinson Vacutainer 
Systems, UK).  
Preparation of Platelet Poor Plasma 
Lithium heparin anticoagulated blood was used for the preparation of platelet poor 
plasma. Blood was centrifuged at 1,500G for 10 minutes at 20oC and the plasma 
supernatant collected. Plasma was stored in 300μl aliquots at -80oC until required. 
Plasma samples were then thawed at room temperature prior to further centrifugation 
at maximum speed for 2 minutes to ensure all cellular debris was removed prior to 
use.  
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Preparation of Washed Platelets 
The first 4.5 mls of blood collected was discarded to avoid inadvertent platelet 
activation during venepuncture affecting the results. The remaining citrate 
anticoagulated blood was centrifuged at 900 rpm for 20 minutes at 20oC with no brake 
to produce PRP. 0.3M citric acid was added to the PRP to achieve a PH of 6.4 in order 
to prevent unwanted platelet activation during the washing process. The PRP was 
further centrifuged at 1,900 rpm for 12 minutes at 20oC to produce a platelet pellet 
and the supernatant was discarded. The platelet pellet was suspended in wash buffer 
(PH 6.5) by gentle pipetting prior to a final centrifugation at 2,200 rpm for 10 minutes 
at 20oC. The supernatant was discarded and the washed platelet pellet was suspended 
in PBS to achieve the desired platelet concentration. The washed platelets were used 
immediately following preparation.  
Plasma swap Protocol 
Washed platelets suspended in PBS were separated into three 100μl aliquots. The first 
aliquot was added to 100μl of autologous plasma, the second aliquot was added to 
100μl of allogeneic control plasma and the third aliquot was added to 100μl of plasma 
from an IPF patient. The end result was 3 platelet suspensions representing autologous 
control, allogeneic control and IPF samples.   
Preparation of HUVEC 
HUVEC were cultured in Endothelial Cell culture medium containing supplied 
supplements (Promocell GmbH, Heidelberg, Germany) (table 12). HUVEC derived from 
passages four to five were grown to confluence in T75 cell culture flasks at 37oC in an 
atmosphere containing 5% CO2 before being harvested using trypsin. Serum free 
media was added to abort the action of trypsin and the HUVEC in suspension were 
centrifuged at 1,500G for 5 minutes to form a pellet. The supernatant was discarded 
and the HUVEC were suspended in serum free media to obtain the desired 
concentration. HUVEC in suspension were agitated continuously to prevent adhesion 
to the walls of the container prior to use in the platelet-endothelial cell adhesion 
assay.  
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Foetal Calf Serum    
Endothelial cell growth supplement 
Recombinant human epidermal growth factor 
Recombinant human fibroblast growth factor 
Hydrocortisone 
Penicillin 
Streptomycin 
0.02ml/ml 
0.004ml/ml 
0.1ng/ml 
1ng/ml 
1μg/ml 
100μg/ml 
100U/ml 
Table 12. Endothelial cell culture medium supplements 
Platelet-Endothelial Adhesion Assay 
Platelet-endothelial adhesion was assessed in suspension. Twenty microliters of 
platelets suspended in autologous control, allogeneic control and IPF plasma were 
added to separate eppindorfs containing 20μl of HUVEC suspended in serum free 
media. The ratio of platelets to HUVEC in each suspension was 10 to 1. The 
suspensions containing platelets and HUVEC were incubated with 5μl FITC-conjugated 
anti-CD42b (BD Biosciences, UK) and varying concentrations of the platelet agonist 
ADP (0.1, 1 and 10μM). Samples were made up to 50μl using PBS. Following 20 
minutes incubation samples were fixed by adding 250μl 1% paraformaldehyde.  HUVEC 
were identified on flow-cytometry by their forward and side scatter characteristics and 
confirmed by labelling a separate sample with PE conjugated anti-CD31 (BD 
Biosciences, UK). A separate experiment confirmed that no unbound platelets 
appeared within the HUVEC gate in resting state or following activation with 0.1, 1 and 
10μM ADP. Additionally, it was confirmed that the FL-1 characteristics of HUVEC in the 
presence of FITC-labelled anti CD42b were unchanged following incubation with ADP. 
Therefore, HUVEC can be reliably identified using their forward and side scatter 
characteristics with CD42b positive events representing adherent platelets (figure 24).  
Platelet-endothelial cell adhesion was expressed as the percentage of endothelial cells 
with one or more bound platelets.     
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Flow Cytometry and Data Analysis 
Flow cytometry was performed using a Becton Dickinson FACS Calibur flow cytometer 
(Becton Dickinson, UK). Data were analysed using CellQuest Pro software (Becton 
Dickinson, UK). Statistical analysis was performed using a paired t-test with a p-value 
of <0.05 considered significant. 
4.3 Results 
The 10 IPF patients and 10 allogeneic controls were well matched across all variables 
(table 13).  
The percentage of endothelial cells (±SEM) with one or more adherent platelet was 
significantly increased following incubation of control platelets in IPF plasma compared 
with allogeneic control plasma at basal levels (0.86 ± 0.03% compared to 0.15 ± 0.03% 
respectively, p=0.04) and following platelet stimulation with 0.1μM ADP (0.88 ± 0.3% 
compared to 0.12 ± 0.04% respectively, p=0.04). There was a trend to increased 
platelet endothelial cell adhesion following incubation in IPF patient plasma compared 
with allogeneic control plasma in the presence of 1μM ADP (1.73 ± 0.7% compared to 
0.21 ± 0.04% respectively, p=0.07) and 10μM ADP (0.71 ± 0.21% compared to 0.34 ± 
0.1% respectively, p=0.06) however this failed to reach statistical significance.  
Similarly, platelet endothelial cell adhesion was significantly greater following 
incubation of control platelets in IPF plasma compared to autologous plasma at basal 
levels (0.86 ± 0.03% compared to 0.09 ± 0.03% respectively, p=0.03) and following 
platelet stimulation with 0.1μM ADP (0.88 ± 0.3% compared to 0.16 ± 0.04%, p=0.03) 
and 10μM ADP (0.71 ± 0.21% compared to 0.26 ± 0.08%, p=0.03).  
There was no significant difference in platelet-endothelial adhesion between control 
platelet incubated in autologous and allogeneic control plasma at basal levels (0.09 ± 
0.03% compared to 0.15 ± 0.03% respectively, p=0.05) and following stimulation with 
0.1μM ADP (0.16 ± 0.04% compared to 0.12 ± 0.04% respectively, p=0.4), 1μM ADP 
(0.41 ± 0.14% compared to 0.21 ± 0.04% respectively, p=0.11), and 10μM ADP (0.26 ± 
0.08% compared to 0.34 ± 0.1 respectively, p=0.13). Platelet-endothelial cell adhesion 
at basal levels and following platelet stimulation with ADP is displayed in figures 25-
29). 
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IPF 
 
Controls 
 
P-value 
Number (n) 
Age in years – Mean (SD) 
Gender (%) 
- Male 
- Female 
Comorbidities 
- Malignancy 
- TIA/CVA 
- Hypertension 
- Diabetes mellitus 
- GER 
- COPD 
- Atrial Fibrillation 
Smoking Status 
- Current 
- Ex-smoker 
- Non-smoker 
- Unknown 
10 
74(8) 
 
6(60) 
4(40) 
 
0 
1 
1 
1 
0 
2 
1 
 
2 
1 
4 
3 
10 
72 (11) 
 
7(70) 
3(30) 
 
1 
0 
0 
0 
1 
3 
0 
 
0 
4 
4 
2 
- 
0.60 
 
0.86 
0.86 
 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
 
0.47 
0.30 
1.35 
1.00 
Table 13. Baseline characteristics of IPF patients and allogeneic controls.  
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Figure 24. Scatter plot demonstrating forward and side scatter characteristics of 
HUVEC (A) and quadrant plot demonstarting FL-1 and FL-2 characterisitcs of HUVEC 
labelled with FITC-conjugated IgG isotype control (B). (C-H) Quadrant plots 
demonstrating FL-1 and FL-2 characterisitcs of HUVEC and control platelets labelled 
with FITC-conjugated CD42b suspended in allogeneic control plasma in basal 
conditions (C) and the same sample with the addition of 1μM ADP (D), IPF plasma in 
basal conditions (E) and the same sample with the addition of 1μM ADP (F), IPF 
plasma in basal conditions (G) and the same sample with the addition of EDTA (H). 
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Figure 25. Platelet-endothelial adhesion expressed as the percentage of endothelial 
cells with one or more adherent platelets. * p = <0.05, NS p = ≥0.05 
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Figure 26. Dot plot demonstrating the percentage of endothelial cells with one or 
more adherent platelets following incubation of control platelets in autologous, 
allogeneic and IPF plasma in basal conditions. 
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Figure 27. Dot plot demonstrating the percentage of endothelial cells with one or 
more adherent platelets following incubation of control platelets in autologous, 
allogeneic and IPF plasma following platelet stimulation with 0.1μM ADP. 
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Figure 28. Dot plot demonstrating the percentage of endothelial cells with one or 
more adherent platelets following incubation of control platelets in autologous, 
allogeneic and IPF plasma following platelet stimulation with 1μM ADP. 
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Figure 29. Dot plot demonstrating the percentage of endothelial cells with one or 
more adherent platelets following incubation of control platelets in autologous, 
allogeneic and IPF plasma following platelet stimulation with 10μM ADP. 
4.4 Discussion 
This study demonstrates increased platelet-endothelial cell adhesion following the 
incubation of control platelets in IPF plasma compared to incubation in autologous and 
allogeneic control plasma. This confirms that the previously described increased 
platelet reactivity in IPF patients has a functional effect and provides evidence of a 
potential pathogenic mechanism.  
Patients and controls were well matched in this experiment with no significant 
difference in age, gender or co morbidities.  
In this study, FITC-labelled CD42b monoclonal antibody (BD Biosciences, UK) was used 
to label platelets. It is important to consider that HUVEC have been reported to 
express CD42b (GPIbα) (166) and it has been implicated in platelet-endothelial 
adhesion (85). However, incubation of HUVEC with the FITC-labelled CD42b 
monoclonal antibody (BD Biosciences, UK) in the absence of platelets did not result in 
any change in the FL-1 characteristics at basal levels or following stimulation with ADP 
(data not shown). It is therefore safe to conclude that the change in FL-1 
 92 
characteristics following incubation with platelets in plasma is due to platelet adhesion 
and not due to a change in HUVEC CD42b expression.    
Platelet-endothelial adhesion assays are often performed under flow conditions using 
a flow-chamber in an attempt to replicate conditions in physiological and disease 
states. However, it is recognised that platelets predominantly adhere to matrix 
proteins and therefore measuring platelet adhesion to endothelial cells that are 
adherent to wells makes it difficult to differentiate platelet-endothelial binding from 
platelets adhering to exposed matrix. Some investigators use fixed endothelial cells to 
maintain confluence and try to overcome this. However, this method can have an 
effect on receptor function and does not completely eliminate the problem (85). 
Assessing platelet-endothelial adhesion in suspension removes the potential for 
platelet-matrix interactions and therefore allows an accurate assessment (85). In this 
study HUVEC were harvested and suspended in serum free media prior to incubation 
with control platelets suspended in IPF or control plasma. This is a novel method of 
measuring platelet-endothelial cell adhesion with previously described assays 
performing the incubation step in HUVEC coated wells prior to mechanical harvesting, 
suspension and flow cytometry (85). However, for the purposes of this study, in order 
to prevent a perceived risk of dissociation of platelets and endothelial cells during 
harvesting, it was decided to perform the incubation step in suspension and therefore 
without the need for further manipulation prior to flow cytometry. This does have the 
potential drawback that matrix proteins that are normally minimally expressed on the 
luminal surface of endothelial cells but more readily expressed on the abluminal 
surface may have been exposed (85). However, the purpose of this study was not to 
identify the mechanism of platelet-endothelial adhesion or to replicate physiological 
conditions in the pulmonary microvasculature. This study aimed to test the hypothesis 
that control platelets incubated in IPF plasma would exhibit greater adhesion to 
endothelial cells than platelets incubated in control plasma. Therefore, despite the 
methodological limitations, this study has achieved its aim and confirmed the 
hypothesis.  
In keeping with previous studies of resting platelets and HUVEC, the observed platelet-
endothelial adhesion was low in all 3 groups (85). It is worth noting that the observed 
platelet-endothelial adhesion was divalent cation dependent as evidenced by the 
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absence of adhesion in the presence of EDTA. Therefore, the use of citrate as an 
anticoagulant following venepuncture may have resulted in lower than expected levels 
of adhesion as described in chapter 3. Interestingly, platelet-endothelial adhesion did 
not alter significantly following platelet stimulation with the agonist ADP. A previous 
study of platelet-endothelial cell adhesion in suspension demonstrated increased 
adhesion in response to platelet stimulation with thrombin (85). This mechanism of 
platelet activation was not investigated in this study because platelet stimulation with 
the thrombin analogue TFLLR in previous assays had resulted in wider variation and 
less reproducibility than ADP.   
Platelet-endothelial cell interactions have a number of potential consequences. It is 
recognised that activated platelets can alter endothelial cell expression of cell 
adhesion molecules and the release of chemotactic cytokines. An ex vivo study of 
HUVEC incubated for 6 hours with ADP stimulated platelets demonstrated increased 
ICAM-1 expression on the endothelial cell surface and increased release of monocyte 
chemotactic protein-1 (MCP-1), a cytokine that is important in the recruitment of 
macrophages (167). This was shown to be due to activation of the transcription factor 
nuclear factor - κB (NF-κB) that is known to regulate MCP-1 and ICAM-1 gene 
expression (167). These changes were not observed following incubation of HUVEC 
with resting platelets or ADP alone confirming that this effect is due to the activated 
platelets. Resting platelets can also affect endothelial cell expression of surface 
adhesion molecules (168). In a model of platelet-endothelial adhesion using brain 
microvascular endothelial cells (MVECs), few resting platelets were noted to adhere to 
the endothelial surface. When the MVECs were stimulated with TNF, increased platelet 
adhesion was observed followed by fusion of the platelet and endothelial membranes 
resulting in the formation of dense granules and incorporation of a portion of the 
platelet membrane into the luminal membrane of the endothelial cell (168).  
Therefore, platelet-endothelial adhesion in the presence of either platelet activation or 
endothelial activation can result in altered endothelial adhesive properties. Up-
regulation of ICAM-1 is recognised to play an important role in leukocyte adhesion and 
transmigration (169;170) and has been implicated in platelet-endothelial adhesion 
(144;171). Interestingly, platelet binding and fusion with TNF activated microvascular 
endothelial cells also increases leukocyte adhesion but also resulted in endothelial 
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injury that was related to the number of platelets and concentration of TNF-α (168). In 
studies of platelet-leukocyte adhesion, it has been demonstrated that adherence of 
activated platelets to neutrophils and monocytes also results in activation of NF-κB and 
is associated with increased production of inflammatory cytokines including Il-1β, Il-8 
and MCP-1 (172). This effect is reduced when platelet-leukocyte adhesion is inhibited 
by P-selectin blockade (172). As previously described, over expression of Il-1β in the 
lung has been implicated in local inflammation with tissue injury and subsequent 
fibrosis associated with transient elevation of PDGF and prolonged elevation of TGF-β 
in bronchoalveolar lavage fluid of mice (43). In addition to platelets ability to increase 
leukocyte production of Il-1β, platelets also contain mRNA for the Il-1β precursor pro-
Il-1β (79). Following activation, platelets have been demonstrated to produce and 
release Il-1β with resulting alteration of endothelial cell adhesive properties increasing 
leukocyte adhesion and transmigration (79).  
4.5 Conclusion 
The series of experiments in chapter 3 demonstrate increased platelet-monocyte 
binding following agonist induced platelet activation in IPF patients. The experiment in 
this chapter demonstrates increased platelet-endothelial binding in platelets incubated 
in IPF patient’s plasma. Adherence of activated platelets to leukocytes is known to 
contribute to local inflammation (172) and adherence of activated platelets to 
endothelial cells alters endothelial adhesive and signalling properties (167). Although it 
is not possible to conclude whether the increased platelet reactivity in IPF is a primary 
event resulting in fibrosis or a response to the pulmonary fibrotic process, the 
observed increase in platelet-monocyte and platelet-endothelial adhesion has 
potential functional consequences. Similar effects have been described in patients with 
vascular disease (172;173) and therefore this finding in IPF provides important insight 
into the epidemiological association between these conditions. Indeed, it also provides 
a potential mechanism by which the pulmonary fibrotic process may be perpetuated: 
platelet-endothelial adhesion in the pulmonary microcirculation; platelet activation 
and degranulation with release of pro-inflammatory and pro-fibrotic mediators (e.g. Il-
1β, PDGF, and TGF-β); and platelet-leukocyte interactions with resulting potentiation 
of their inflammatory potential. 
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5. Plasma Factors in Idiopathic Pulmonary Fibrosis 
5.1 Evaluation of plasma D-dimer as a marker of fibrinolysis in idiopathic pulmonary 
fibrosis 
5.1.1 Introduction 
D-dimer is the final breakdown product of cross-linked fibrin and represents 
endogenous fibrinolysis. The D-dimer antigen is produced during the formation of the 
fibrin clot and can be detected by commercially available assays following fibrinolysis. 
The first step in fibrin clot formation is thrombin mediated cleavage of fibrinogen to 
produce fibrin monomers. Each monomer has two D-domains separated by a single E-
domain. Fibrin monomers have a high affinity to form non-covalent bonds between 
the D-domain and the D or E-domain on adjacent monomers forming a fibrin 
protofibril. Thrombin remains associated with fibrin throughout this process and 
mediates factor XIII activation to factor XIIIa. Factor XIIIa promotes the formation of 
covalent bonds between D-domains of adjacent fibrin monomers in the fibrin 
protofibril to form the D-dimer antigen and create a cross-linked fibrin polymer. The D-
dimer antigen remains undetectable until plasmin mediated cleavage of the fibrin 
polymer occurs releasing fibrin degradation products with exposed D-dimer antigen. 
This can occur prior to formation of an insoluble fibrin clot (ie plasmin mediated 
cleavage of a soluble cross-linked fibrin polymer prior to its incorporation into an 
insoluble fibrin clot) or during degradation of an established insoluble fibrin clot (174). 
D-dimer assays utilize monoclonal antibodies that recognise an exposed epitope on the 
cross-linked D-domain of fibrin. D-dimer detection therefore requires the formation of 
a cross-linked fibrin polymer with D-dimer formation mediated by thrombin and factor 
XIIIa and subsequent cleavage by plasmin (174).  
Measurement of blood D-dimer level is widely used in clinical practice to exclude VTE 
in patients with a low probability stratified using clinical scoring systems. However, an 
elevated D-dimer is not specific to thromboembolic disease and will be present in any 
condition resulting in fibrin formation including but not limited to sepsis, acute 
cardiovascular events, malignancy and pregnancy. It is therefore useful as an indicator 
of activation of the coagulation system. Kubo et al. observed that D-dimer levels were 
elevated in IPF patients and that it increased during an acute exacerbation in a 
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randomised control trial of anticoagulation in IPF (128). It is recognised that there is an 
imbalance in haemostatic mechanisms in the lungs of patients with IPF with the 
environment in the alveolar compartment favouring fibrin deposition (175). However, 
despite epidemiological studies demonstrating an increased prevalence of thrombotic 
vascular disease in IPF patients the systemic mechanisms underlying this have not 
previously been described.   
D-Dimer levels have previously been studied in patients with sarcoidosis and have 
been found to be elevated in 30-39% of patients with elevated levels being associated 
with lung parenchymal involvement and resulting symptoms of breathlessness and 
abnormal lung function measurements (176;177). A study of BAL fluid in sarcoidosis 
demonstrated that D-Dimer was detectable in the BAL fluid of patients but not in 
controls and that the D-Dimer levels correlated with the degree of lymphocytic 
alveolitis (178). This supports a possible role for D-dimer measurement in the 
evaluation of patients with interstitial lung disease and suggests a relationship 
between activation of the coagulation system and parenchymal lung disease. However, 
the nature of this relationship is unclear and it is not possible to conclude whether it is 
cause or effect.  
It is possible that D-dimer elevation may have prognostic implications. A study of D-
dimer in systemic lupus erythematosus, a connective tissue disease with multisystem 
involvement, reported an increased rate of thrombotic events in those with an 
elevated D-dimer level measured during routine follow-up (179). This has important 
implications for patient management and it is not clear whether these patients would 
benefit from routine anticoagulation. The role of D-dimer in IPF for predicting future 
thrombotic events has not previously been investigated.   
We have measured the plasma D-dimer concentration of stable IPF patients and 
prospectively followed their course over 2 years to assess disease progression defined 
by lung function decline, incidence of acute exacerbations of IPF, incidence of 
thromboembolic disease, incidence of cardiovascular disease and death. 
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5.1.2 Method 
Patient Selection 
Patients were recruited from the interstitial lung disease clinic at a large University 
Hospital. A total of 29 patients with a diagnosis of IPF in accordance with the ATS/ERS 
criteria (9) entered the study. 20 control patients without fibrotic lung disease were 
recruited from other hospital out-patient clinics. All patients were stable at the time of 
blood sampling being clinically free from an exacerbation or any other acute 
inflammatory, neoplastic or thrombotic process. Patients were followed up 
prospectively for a two year period from the time of blood sampling and assessed for 
the following: acute exacerbation, venous thromboembolic event, acute cardiovascular 
event, disease progression defined by lung function decline, and death. Baseline lung 
function was taken as the lung function measurements performed closest to the time 
of blood sampling. Due to inter individual variation in the length of time between 
baseline and subsequent lung function measurements the lung function change is 
expressed as change in FVC and TLCO over 1 year.  
Blood Sampling and D-Dimer Assay 
Venous blood was collected from an antecubital vein using a 21 gauge butterfly needle 
(Becton Dickinson Vacutainer Systems, UK) and collected into a vacutainer tube 
anticoagulated with 102 IU lithium heparin (Becton Dickinson Vacutainer Systems, UK). 
Plasma was collected by centrifuging the blood at 1,500G for 10 minutes at 20oC and 
the supernatant was collected. The plasma was stored in 300μl aliquots at -80oC prior 
to thawing at room temperature prior to testing. HemosIL D-dimer HS automated latex 
enhanced immunoassay was used to measure plasma D-dimer level (Instrumentation 
Laboratory Company, Bedford, MA). A cut off of 250 ng/ml was used as the upper limit 
of normal in keeping with local clinical practice for the exclusion of VTE.  
The difference in proportion of patients with an elevated D-dimer in IPF patients and 
controls was assessed using a 2 x 2 contingency table and Fishers Exact Test. The 
difference between mean D-dimer levels in IPF patients compared with controls was 
assessed using an unpaired t-test. A p-value of <0.05 was considered statistically 
significant.  
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5.1.3 Results 
There was no significant difference in age, gender, prevalence of comorbid conditions 
or smoking status between IPF patients and controls (table 14). 
The D-dimer was elevated above the 250 ng/ml cut off in 12/29 IPF patients. The mean 
D-dimer level (±SEM) was 253.1±27.2 ng/ml. The D-dimer was elevated above 
500ng/ml in 2/29 IPF patients.  
The D-dimer was elevated above the 250 ng/ml cut off in 4/20 control patients with 
1/20 control patients having a D-dimer above 500 ng/ml. The difference in the number 
of IPF patients and controls with a D-dimer above 250 ng/ml was not statistically 
significant (p=0.14). The mean D-dimer in the control group was 198.2±28.1 ng/ml and 
did not differ significantly from IPF patients (p=0.18) (figure 30). Baseline lung function 
data was available for 25/29 patients. Serial lung function measurements were 
available for 18/29 patients. There was no difference in baseline lung function 
measurements or change in lung function over time between IPF patients with an 
elevated D-dimer and IPF patients with a D-dimer within normal range (table 15). 
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Figure 30. Scatter plot demonstrating the distribution of D-dimer levels (ng/ml) in IPF 
and controls. Dotted line represents the 250 ng/ml cut off.  
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IPF 
 
Controls 
 
P-value 
Number (n) 
Age in years – Mean (SD) 
Gender (%) 
- Male 
- Female 
Comorbidities (%) 
- Malignancy 
- TIA/CVA 
- Hypertension 
- Diabetes mellitus 
- GER 
- COPD 
- Sleep apnoea 
- IHD 
Smoking Status (%) 
- Current 
- Ex-smoker 
- Non-smoker 
- Unknown 
29 
69.1 (8.3) 
 
21(72.4) 
8(27.6) 
 
0(0) 
4(13.8) 
6(20.7) 
1(3.4) 
3(10.3) 
5(17.2) 
0(0) 
7(24.1) 
 
8(27.6) 
13(44.8) 
5(17.2) 
3(10.3) 
20 
66.5 (9.8) 
 
11(55) 
9(45) 
 
0(0) 
0(0) 
1(5) 
1(5) 
1(5) 
5(25) 
2(10) 
1(5) 
 
1(5) 
10(50) 
7(35) 
2(10) 
- 
0.33 
 
0.24 
0.24 
 
- 
0.14 
0.22 
1.00 
0.64 
0.72 
0.16 
0.12 
 
0.06 
0.78 
0.19 
1.00 
Table 14. Baseline characteristics of IPF patients and controls 
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Lung Function  Elevated D-dimer Normal D-dimer p-value 
Baseline 
- FVC (L) 
%predicted 
- TLCO (ml/mmHg/Mi) 
% predicted 
Change over 1 year 
- FVC (L) 
- TLCO (ml/mmHg/Mi) 
 
2.98 
88.67 
3.81 
48.55 
 
-0.26 
-0.5 
 
3.39 
100.86 
3.88 
48.29 
 
-0.19 
-1.6 
 
0.33 
 
0.93 
 
 
0.68 
0.23 
Table 15. Lung function at baseline (litres) and lung function decline in 1 year in IPF 
patients with elevated D-dimer (>250ng/ml) and normal D-dimer (≤250ng/ml) 
The all-cause mortality was 4/12 in the elevated D-dimer group and 3/17 in IPF 
patients with D-dimer within normal range (p=0.40). There was no difference between 
the groups with regard to acute exacerbations, venous thromboembolism or acute 
cardiac events (table 16). One patient in the elevated D-dimer group was admitted 
with an acute exacerbation of IPF with no acute exacerbations occurring in the normal 
D-dimer group (p=0.40). One patient in the normal D-dimer group had a deep vein 
thrombosis during the study period while no patients with an elevated D-dimer at 
baseline had a venous thromboembolic event (p=1.00). One patient in the normal D-
dimer group had an acute non-ST elevation myocardial infarction during the study 
period with no acute cardiac events occurring in the elevated D-dimer group (p=1.00). 
Outcome Elevated D-dimer Normal D-dimer p-value 
Number of patients (n) 
All-Cause Mortality 
Acute Exacerbation of IPF 
Cardiovascular Event 
VTE 
12 
4 
1 
0 
0 
17 
3 
0 
1 
1 
- 
0.40 
0.40 
1.00 
1.00 
Table 16. Adverse events in IPF patients with elevated D-dimer (>250ng/ml) and 
normal D-dimer (≤250ng/ml) 
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5.1.4 Discussion 
The plasma D-dimer level was elevated in 41% of IPF patients indicating increased 
activation of the coagulation and fibrinolytic systems. Interestingly the plasma D-dimer 
level was also elevated in 20% of control patients and the difference between the two 
groups did not reach statistical significance. However, an elevated D-dimer represents 
increased activation of the coagulation system and the resulting presence of increased 
concentration of fibrinogen degradation products.  
In this study we did not demonstrate any association between an elevated D-dimer 
and adverse clinical outcomes or with disease severity assessed by lung function at 
baseline or decline over time. During the follow-up period we observed fewer adverse 
events than expected with only 1 participant experiencing an acute exacerbation, 1 
participant having an acute cardiovascular event and 1 participant having a deep vein 
thrombosis. Likewise, the mortality rate in this study was lower than expected with a 
total of 8 deaths during the 2-year follow-up period representing 26% two-year 
mortality. In light of the low incidence of adverse events it was underpowered to 
detect a difference between the two groups.  
The rate of lung function decline observed in our cohort was lower than reported in a 
number of large randomised trials of potential new IPF therapies (180;181). A previous 
study of anticoagulation in 56 IPF patients with 3-year follow up reported a 57% 
mortality rate with 33 admissions with acute exacerbations of IPF (128). The patients in 
this study were all treated with prednisolone with half being randomised to 
additionally receive anticoagulation. In contrast, none of the patients reported in our 
study were taking corticosteroids or anticoagulants. A recent randomised, placebo-
controlled trial was stopped early due to increased mortality and hospitalisation in the 
group receiving immunosuppression (30). This suggests that immunosuppression 
including corticosteroids may have a deleterious effect on outcome in IPF patients. 
Additionally, a recent randomised, placebo controlled trial of the anticoagulant 
warfarin in IPF was stopped early due to increased mortality in the warfarin group (23). 
Therefore, the increased adverse events noted by Kubo et al. may be in part due to 
their drug therapy potentially explaining the comparatively small number of adverse 
events in our untreated cohort of IPF patients.  
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5.1.5 Conclusion 
There was no significant difference in D-dimer concentration between IPF patients and 
controls in this study. Despite this, the plasma D-dimer was elevated in 41% of IPF 
patients indicating increased activation of the coagulation and fibrinolytic systems in 
the systemic circulation. The interplay between thrombotic and fibrinolytic systems 
appear important in IPF. However, it is clear that the mechanisms underlying this and 
potential therapeutic targets remain incompletely understood. In light of the 
recognised association with thromboembolic disease it would seem reasonable to 
hypothesise that anticoagulation would confer benefit. However, this has recently 
been shown to be associated with adverse outcomes using the anticoagulant warfarin 
(23). It is noteworthy that the reported adverse outcomes were respiratory in origin 
and not related to bleeding. This poses the question whether warfarin is having a 
deleterious effect beyond the desired effect of preventing thrombosis. Therefore, the 
role of anticoagulation warrants further consideration in IPF in order to identify 
potential mechanisms of harm caused by warfarin and consider the role of alternative 
means of anticoagulation.       
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5.2 Evaluation of plasma markers of endothelial cell activation and injury 
5.2.1 Introduction 
The endothelium forms a barrier between the pulmonary circulation and the lung 
parenchyma. The endothelium has an important role in regulating the adhesion and 
trafficking of inflammatory cells, preventing unwanted platelet activation and 
thrombus formation. Maintenance of normal endothelial function is therefore 
important in maintaining vascular integrity, patency and facilitating appropriate 
transfer of substances between the vascular space and the interstitium. Endothelial 
dysfunction can therefore have a number of adverse affects including inappropriate 
platelet activation, thrombus formation and adhesion and transmigration of 
inflammatory cells. In addition to causing local tissue injury there is the potential for 
endothelial dysfunction to lead to systemic effects through altered function of 
circulating cells. In order to investigate the potential role of endothelial dysfunction in 
IPF as a potential link with vascular disease and a potential cause for the abnormal 
platelet responses demonstrated in the previous experiments this study will measure 
soluble thrombomodulin, soluble vascular endothelial adhesion molecule - 1 (sVCAM-
1) and vWF in the plasma of IPF patients and controls.   
Soluble Thrombomodulin 
Thrombomodulin is a transmembrane glycoprotein expressed on the surface of 
endothelial cells. It acts as a receptor for thrombin and has important anticoagulant 
properties through activation of protein C (182;183) and reducing the ability of 
thrombin to form fibrin clots and activate platelets (183). In addition to the protective 
effects thrombomodulin exerts against thrombosis, through activation of protein C it 
also has numerous cytoprotective and anti-inflammatory affects mediated by protease 
activated receptor-1 (PAR-1) and endothelial protein C receptor (EPCR) (184). One of 
the cytoprotective affects of activated protein C is the alteration of endothelial cell 
gene expression of pro-inflammatory pathways including down regulation of NF-κB 
subunits resulting in decreased NF-κB binding and down regulation of downstream 
genes including ICAM-1, VCAM and E-selectin (185). Activated protein C also exerts 
protective affects through regulating endothelial cell apoptosis and preserving 
endothelial barrier function (184;185). Thrombomodulin also has anti-inflammatory 
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effects that are not dependent on activated protein C by directly inhibiting neutrophil 
binding through ICAM-1 dependent and independent pathways (186). This affect is 
mediated by thrombomodulins NH(2)-terminal domain that has homology to the C-
type lectins (186). Mice deficient in this extracellular domain have reduced survival and 
increased neutrophil accumulation in the lung following lipopolysaccharide (LPS) 
inhalation (186). Therefore, thrombomodulin expression on endothelial cells has 
important roles in protecting against thrombosis and inflammation.  
In addition to the membrane bound glycoprotein, a soluble form of thrombomodulin is 
found in the plasma, serum and urine (187). TNF-α is known to be associated with 
reduced cell surface expression of thrombomodulin with suggestion that this occurs 
due to alterations in gene expression and internalisation of the surface molecule (187). 
However, diseases associated with an inflammatory response, for example systemic 
lupus erythematosus, have been associated with increased serum thrombomodulin 
(188).  This has subsequently been demonstrated to be due to neutrophil dependent 
damage of TNF-α stimulated endothelial cells and resulting thrombomodulin release 
(187).  Therefore, in certain conditions associated with endothelial activation and 
injury, endothelial cell surface expression of thrombomodulin is decreased and this is 
associated with a release of soluble thrombomodulin into the plasma.  
Soluble thrombomodulin levels have been found to be elevated in patients with 
vascular diseases including stroke (189) and in patients with atrial fibrillation who 
develop thrombotic events including stroke, myocardial infarction and pulmonary 
embolism (190). Soluble thrombomodulin has been used as an indicator of endothelial 
injury and dysfunction in conditions including vascular disease (191), renal disease 
(192) including following renal transplant (193) and connective tissue disease (194-
196). Soluble thrombomodulin has been shown to correlate with the number of 
circulating endothelial cells, another surrogate marker of vascular injury (197). 
Soluble Vascular Endothelial Cell Adhesion Molecule (sVCAM) 
VCAM-1 is a member of the immunoglobulin gene superfamily that is expressed on 
endothelial cells where it is responsible for adhesion and transmigration of monocytes 
and lymphocytes through interactions with its ligand, very late activation antigen-4 
(VLA-4) (198). VCAM-1 expression on endothelial cells occurs in association with ICAM-
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1 and E-selectin following stimulation with TNF-α, Il-1β and LPS but VCAM-1 also has 
specific regulatory mechanisms, for example Il-4 up regulates TNF-α induced VCAM-1 
expression while down regulating ICAM-1 and E-selectin expression (198;199). VCAM-1 
expression is felt to be particularly sensitive to oxidative stress (198;200). TNF-α 
induced endothelial adhesion molecule expression is associated with NF-κB activation 
and can be suppressed by treatment with antioxidants and NO (200;201).  
Increased VCAM-1 expression has been described in areas of the vascular endothelium 
prone to the development of atherosclerotic plaques and in areas bordering existing 
plaques (202). In an animal model of atherogenesis using apolipoprotein E knockout 
mice with varying degree of VCAM-1 gene knockout there was a dose dependent 
reduction in VCAM-1 expression associated with reduced monocyte adherence and 
atherogenesis demonstrating an important role for VCAM-1 in the development of 
vascular diseases including cardiovascular disease (203). Additionally, a study of 
glomeruli in end stage renal failure secondary to age related glomerulosclerosis found 
that old glomeruli have increased VCAM-1 expression in addition to other adhesion 
molecules that was dependent on NF-κB up-regulation with a resulting phenotype that 
was pro-inflammatory, profibrotic and procoagulable (204). This described phenotype 
appears to have a number of parallels with IPF. 
A previous study assessed VCAM-1 expression in lung tissue from 9 IPF patients using 
immunohistochemistry and did not detect any increased expression (205). However, 
increased VCAM-1 expression on endothelial cells is known to be associated with 
pulmonary fibrosis secondary to irradiation (206). 
sVCAM-1 is used as a marker of endothelial dysfunction and has been investigated in a 
number of systemic diseases (207). Soluble adhesion molecules including ICAM-1, E-
selectin and VCAM-1 have been shown to be elevated in patients with systemic 
sclerosis, a connective tissue disease often associated with interstitial lung disease 
(208). A study of plasma concentrations of adhesion molecules in a large cohort of IPF 
patients found that elevated levels of sVCAM were associated with worse outcomes 
including reduced overall survival and progression free survival (209).  
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Von Willebrand Factor (vWF) 
vWF is a multimeric glycoprotein that ranges in molecular weight from 500-10,000kDa 
depending on the number of subunits in the molecule (210). It is present in the plasma 
and is contained within platelet granules and endothelial cell Weibel-Palade bodies 
being released on activation. vWF has two roles that are essential in maintaining 
normal haemostasis: firstly, vWF binds to exposed subendothelial matrix where it 
interacts with platelet receptors resulting in the activation of GPIIb/IIIa which mediates 
platelet binding and growth of the platelet thrombus through accumulation of 
circulating platelets (210); secondly, vWF forms a complex with factor VIII in the 
circulation and therefore has an important role in secondary haemostasis.  
Multimeric vWF is produced in endothelial cells from pro-pro-vWF which is cleaved to 
produce pro-vWF and subsequently vWF following a complex series of processing 
events (211). Endothelial cell produced vWF is released into the subendothelial matrix 
and the plasma in addition to being stored in Weibel-Palade bodies. Megakaryocytes 
produce vWF in the same way as endothelial cells however all of it is stored in α-
granules for release following platelet activation (210). As a result, plasma vWF 
originates from direct secretion from endothelial cells following production, release 
from endothelial cell Weibel-Palade bodies following endothelial activation and 
release form α-granules of platelets following platelet activation.  
This study investigates the levels of the recognised markers of endothelial cell 
activation: soluble thrombomodulin, sVCAM and vWF in patients with IPF and controls.    
5.2.2 Methods 
Blood was collected from 26 IPF patients diagnosed according to ATS/ERS consensus 
criteria (9) and 19 control patients with no evidence of fibrotic disease. All patients 
were clinically stable at the time of sampling being free from any evidence of active 
inflammation or other acute inter current illness. Patients were recruited from the 
interstitial lung disease clinic at a large university hospital. Control patients were 
recruited from other hospital out-patient clinics. Soluble thrombomodulin was 
measured in 23 IPF patients and 17 controls. sVCAM and vWF were measured in 21 IPF 
patients and 17 controls.  
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Blood was collected using a 21-gauge butterfly needle from a large antecubital vein 
and collected into a vacutainer tube anticoagulated with 102 IU lithium heparin 
(Becton Dickinson Vacutainer Systems, UK). Plasma was isolated following 
centrifugation at 1500G for 10 minutes at 20oC prior to freezing at -80oC until ready for 
use. Plasma levels of soluble thrombomodulin and sVCAM were measured using ELISA 
(R&D systems, UK).  
The difference in mean concentrations of soluble thrombomodulin and sVCAM were 
tested for statistical significance using an unpaired t-test. A p-value of <0.05 was 
considered statistically significant.  
5.2.3 Results 
Patients were well matched for age and gender. COPD was more prevalent in the 
control group (p=0.02) and more patients in the IPF group were current smokers 
(p=0.03) (table 17). 
The mean (±SEM) plasma thrombomodulin concentration was 5483.1 ± 407.6 pg/ml in 
IPF patients compared with 5267.9 ± 266.7 pg/ml in controls (figure 31). The difference 
was not statistically significant (p=0.69).  
 The mean (±SEM) plasma sVCAM concentration was 885.84 ± 104.75 ng/ml in IPF 
patients compared with 739.40 ± 57.852 ng/ml in controls (figure 32). The difference 
between the two groups was not statistically significant (p=0.13).  
Measurement of the plasma concentration of vWF using ELISA was unsuccessful with 
concentrations in the IPF samples and controls being greater than the highest standard 
in the assay. 
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IPF 
 
Controls 
 
P-value 
Number (n) 
Age in years – Mean (SD) 
Gender (%) 
- Male 
- Female 
Comorbidities 
- Active Malignancy 
- TIA/CVA 
- Hypertension 
- Diabetes mellitus 
- GER 
- COPD 
- Sleep apnoea 
- Atrial Fibrillation 
Smoking Status 
- Current 
- Ex-smoker 
- Non-smoker 
- Unknown 
26 
70.1(7) 
 
17(65.4) 
9(34.6) 
 
0(0) 
2(7.7) 
7(26.9) 
2(7.7) 
3(11.5) 
2(7.7) 
0(0) 
1(3.8) 
 
6(23.1) 
9(34.6) 
7(26.9) 
4(15.4) 
19 
69.2(10.3) 
 
11(57.9) 
8(42.1) 
 
2(10.5) 
1(5.3) 
1(5.3) 
1(5.3) 
1(5.3) 
7(5.3) 
2(5.3) 
0(5.3) 
 
0(0) 
11(57.9) 
4(21.1) 
4(21.1) 
- 
0.73 
 
0.76 
0.76 
 
0.17 
1.00 
0.11 
1.00 
0.63 
0.02 
0.17 
1.00 
 
0.03 
0.14 
0.74 
0.70 
Table 17. Baseline characteristics of IPF patients and Controls 
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Figure 31. Plasma thrombomodulin concentration (pg/ml) in IPF patients and 
controls. 
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Figure 32. Plasma sVCAM concentration (ng/ml) in IPF patients and controls. 
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5.2.4 Discussion 
This study investigated the plasma concentrations of soluble thrombomodulin, sVCAM 
and vWF in IPF patients and controls. There was a slightly higher concentration of 
soluble thrombomodulin and sVCAM-1 in IPF but this was not statistically significant. 
This suggests that the previously described increased platelet reactivity is not a result 
of endothelial dysfunction. However, the small sample size in this study makes it 
difficult to draw firm conclusions regarding the presence or absence of endothelial 
dysfunction in IPF. Indeed, it is likely that IPF has a prolonged preclinical phase prior to 
the diagnosis being made. It is conceivable that a small difference in endothelial 
activation could be present for a prolonged period of time with a cumulative effect 
resulting in the self-perpetuating fibrotic process. It is also true that there is significant 
heterogeneity in IPF phenotype between individuals that should be considered when 
analysing the results of small studies. Therefore, despite this study not demonstrating 
a significant difference in markers of endothelial activation it is important not to 
dismiss this possibility completely. 
There was a higher proportion of patients with COPD in the control group compared 
with the IPF group in this study. This reflects the method of recruitment of control 
subjects from other hospital outpatient clinics. COPD is known to be associated with 
increased platelet activation (138) and inflammation within the lung so it is essential to 
consider the possible implications of the increased prevalence of COPD on the 
measured markers of endothelial activation. There is limited evidence regarding the 
effects of COPD on VCAM expression with data being extrapolated from studies of 
smokers and non-smokers (212). However, sVCAM-1 has been demonstrated to be 
increased during an acute exacerbation of COPD but returned to control levels 
following treatment (213). The patients in this study were all free from an 
exacerbation at the time of blood sampling and therefore any potential effect as a 
result of comorbid COPD will be minimised.  It is also important to consider the affect 
of COPD on soluble thrombomodulin. A study of COPD patients and controls found 
that there was no difference in soluble thrombomodulin levels at rest however 
following exercise there was a significant increase in soluble thrombomodulin in COPD 
patients with a bronchitic phenotype compared to those with predominant 
emphysema and controls (214). All patients included in this study were rested prior to 
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blood sampling and therefore the described increase in thrombomodulin on exertion 
in COPD is not relevant to this patient cohort.  
There was a higher proportion of IPF patients that were current smokers at the time of 
blood sampling compared to controls. Previous studies of the effect of inhaling 
cigarette smoke acutely and in chronic smokers during cessation demonstrated that 
cigarette smoke significantly increased plasma levels of vWF that improved during 
smoking cessation (215;216) but they did not demonstrate any significant difference in 
soluble thrombomodulin concentrations (216-218). However, the ability of 
thrombomodulin to bind thrombin does appear to be impaired by cigarette smoke 
(219). The increased proportion of current smokers in the IPF group may therefore 
have affected the plasma vWF level however it is not likely to have affected soluble 
thrombomodulin levels. There is conflicting evidence regarding the effects of cigarette 
smoking on VCAM-1 expression. Experimental models have demonstrated increased 
VCAM-1 expression on endothelial cells exposed to cigarette smoke (220;221) and 
smokers with cardiovascular disease have been shown to have increased plasma levels 
of sVCAM compared with non-smokers with cardiovascular disease (222). However, a 
study of pulmonary endothelial VCAM expression in lung biopsy specimens from 
smokers and non-smokers found that there was no difference between the two groups 
(223). It is therefore difficult to conclude whether the increased proportion of current 
smokers in the IPF group will affect the sVCAM-1 concentration measured in this study.  
Unfortunately measurement of plasma vWF was unsuccessful due to the measured 
plasma concentration of all samples being greater than the highest concentration of 
standard. As a result it was not possible to accurately measure sample concentration 
of vWF. In order to resolve this it will be necessary to repeat the ELISA with further 
sample dilution however this was not possible during the timeframe of this study.  
A recent study of 241 IPF patients identified sVCAM-1 as a predictor of poor outcome 
when plasma concentrations measured using Luminex technology exceeded a 
threshold of 390 to 418 ng/ml (209). It is noteworthy that the mean plasma 
concentration of sVCAM-1 in both IPF and control groups in this study were almost 
double the level of this cut off. The reason for the difference in sVCAM-1 in this study 
is not clear although a different methodology was used to quantify the concentration 
of sVCAM. Another recent study of sVCAM-1 in a cohort of patients with rheumatoid 
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arthritis and controls yielded sVCAM-1 concentrations in the control group similar to 
those observed in this study (224).   
In order to definitively assess the role of the endothelium in IPF it will be necessary to 
perform a study with a large, well matched sample of IPF patients and controls with 
adequate power to identify an intergroup difference of the magnitude described in this 
study. It would also be prudent to perform assessment of endothelial dysfunction by 
measurement of peripheral arterial tone changes following a period of ischemia. This 
can be measured non-invasively in the peripheral arterial beds using Endo-PAT.    
5.2.5 Conclusion 
This study did not demonstrate a significant difference in the measured markers of 
endothelial dysfunction in IPF patients and controls. A study with larger sample size is 
required to conclusively assess markers of endothelial dysfunction in IPF with greater 
power to detect small intergroup differences.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
6. Concluding Remarks 
In this thesis we report the first description of abnormal platelet responses in patients 
with IPF. We conclusively demonstrate increased platelet reactivity in IPF patients 
compared with controls that was reproducible across the three measured markers of 
platelet activation and two activation pathways. This observation is considered even 
more significant in light of the high proportion of patients with COPD in the control 
group; a condition also recognised to be associated with increased platelet reactivity. 
The observation that incubation in IPF plasma can induce the same effect in control 
platelets suggests that there is a factor in the plasma of IPF patients that is resulting in 
platelet activation or priming platelets for activation in response to another stimulus. 
In light of the recognised proinflammatory and profibrotic potential of platelets and 
the ability of platelets to alter the phenotype of leukocytes and endothelial cells there 
is little doubt that if inappropriately activated platelets have the potential to drive or 
perpetuate a fibrotic process. The demonstration that IPF platelets have increased 
propensity to adhere to endothelial cells confirms a functional effect of the observed 
increased platelet reactivity but also provides evidence of a potential pathogenic role 
for platelets in perpetuating fibrosis in IPF.  
The endothelium plays an important role in regulating platelet function. We did not 
demonstrate any evidence of endothelial cell activation in IPF patients compared with 
controls. However, the limited sample size, inter group differences in terms of 
comorbid COPD and smoking status, and technical difficulties in assessing vWF make it 
difficult to draw firm conclusions from this experiment. We also did not demonstrate 
any difference in plasma D-dimer compared with controls but the D-dimer level was 
elevated in almost half of IPF patients suggesting that there is increased activation of 
haemostatic mechanisms. This has been the subject of investigation in large 
randomised, controlled trials with recent evidence to suggest a harmful effect of 
warfarin treatment. This requires further exploration.   
In addition to confirming an abnormal platelet response in IPF patients, the 
experiments described in this thesis lead to further questions guiding future research. 
There are a number of critical factors that require further investigation. It is essential 
to identify the plasma factor responsible for the increased platelet reactivity observed 
in IPF patients. This can be achieved by measuring the known endogenous platelet 
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agonists and inhibitors with a view to serum fractionation and mass spectrometry if 
initial studies prove inconclusive. Platelet function in IPF patients needs to be further 
assessed to include platelet aggregation assays and more detailed studies of platelet-
endothelial adhesion under flow conditions and in the presence of blocking antibodies. 
This would provide greater understanding of the functional implication of the observed 
increased platelet reactivity in IPF and identify the mechanism of increased platelet-
endothelial adhesion. A well conducted randomised controlled trial of antiplatelet 
drugs in IPF would assess the impact of these drugs on clinical outcomes and identify 
the utility of targeting individual platelet pathways. In addition, further evaluation of 
endothelial activation markers in a large IPF patient cohort and non-invasive 
measurement of change in peripheral arterial tone in response to ischaemia would 
provide more definitive evidence of the role of the endothelium in IPF.  
In summary, the series of experiments described in this thesis conclusively 
demonstrate increased platelet reactivity in IPF patients that can be reproduced in 
control platelets following incubation in IPF plasma. There is a resulting alteration in 
platelet function with increased propensity to adhere to endothelial cells. These 
findings open a new avenue of research in IPF with the potential to explore new 
treatment strategies.  
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Definitions 
 
ADP    Adenosine Diphosphate 
ALAT    The Latin American Thoracic Association 
ATS    American Thoracic Society 
BAL    Bronchoalveolar Lavage 
BOOP    Bronchiolitis Obliterans Organising Pneumonia 
BTS    British Thoracic Society 
cGK-1    Cyclin Guanosine Monoposphate Kinase-1 
COP    Cryptogenic Organising Pneumonia 
CFA    Cryptogenic Fibrosing Alveolitis 
COPD    Chronci Obstructive Pulmonary Disease 
CO2    Carbon Dioxide 
CVA    Cerebrovascular Accident 
DETA-NO   Diethylenetriamine Nitric Oxide 
DIP    Desquamative Interstitial Pneumonia 
DVT    Deep Vein Thrombosis 
EDTA    Ethylenediaminetetraacetic acid 
EGF    Epidermal Growth Factor 
ELISA    Enzyme Linked Immunsorbent Assay 
EMT    Epithelial Mesenchymal Transformation 
eNOS    Endothelial Nitric Oxide Synthase 
EPCR    Endothelial Protein C Receptor 
ERS    European Respiratory Society 
FITC    Fluorescein isothiocyanate 
FVC    Forced Vital Capacity 
GER    Gastroesophageal Reflux 
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GIP    Giant Cell Interstitial Pneumonia 
GP    Glycoprotein 
HRCT    High Resolution Computerised Tomography 
HUVEC    Human Umbilical Vein Endothelial Cell(s) 
ICAM-1   Intercellular adhesion molecule - 1 
IHD    Ischaemic Heart Disease 
IIP    Idiopathic Interstitial Pneumonia 
Il    Interleukin     
INR    International Normalised Ratio 
IPF     Idiopathic Pulmonary Fibrosis 
ITIM    Immunoreceptor Tyrosine-Based Inhibitory Motif 
JRS    Japanese Respiratory Society 
LPS    Lipopolysaccharide 
LIP    Lymphoid Interstitial Pneumonia 
L-NAME   L-NG-Nitroarginine Methyl Ester 
MCP-1    Monocyte Chemotactic Protein-1 
mRNA    Messenger Ribonucleic Acid 
MVECs    Microvascular Endothelial Cells 
NF-κB    Nuclear Factor - κB 
NSIP    Non Specific Interstitial Pneumonia 
PAR-1    Protease Activated Receptor-1 
PAI    Plasminogen Activator Inhibitor 
PAI-1    Plasminogen Activator Inhibitor type 1 
PAI-2    Plasminogen Activator Inhibitor type 2 
PBS    Phosphate Buffered Saline  
PDGF    Platelet Derived Growth Factor 
PE    Pulmonary Embolism 
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PE-    Phycoerythrin 
PECAM-1    Platelet Endothelial Cell Adhesion Molecule -1  
PF4    Platelet Factor 4  
PRP    Platelet Rich Plasma 
PSGL-1    P-Selectin Glycoprotein Ligand - 1 
PVD    Peripheral Vascular Disease 
RNA    Ribonucleic Acid 
SD    Standard Deviation 
SDF-1    Stem Cell Derived Factor -1 
SEM     Standard Error of the Mean 
SNP    Single Nucleotide Polymorphism 
sGC    Soluble Guanylyl Cyclase 
sPECAM-1   Soluble Platelet Endothelial Cell Adhesion Molecule 
sVCAM   Soluble Vascular Cell Adhesion Molecule 
TF    Tissue Factor 
TFPI    Tissue Factor Pathway Inhibitor 
TGF-β    Transforming Growth Factor 
TIA    Transient Ischaemic Attack 
TLCO    Carbon Monoxide Transfer Factor 
TNF-α    Tumour Necrosis Factor - α 
tPA    Tissue-Type Plasminogen Activator 
UIP    Usual Interstitial Pneumonia 
UK    United Kingdom 
uPA    urokinase-type Plasminogen Activator 
VASP    Vasodilator-Stimulated Phosphoprotein 
VCAM    Vascular Cell Adhesion Molecule 
sVCAM   Soluble Vascular Cell Adhesion Molecule 
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VLA-4    Very Late Activation Antigen-4  
VTE    Venous Thromboembolism 
vWF    von Willebrand Factor 
 
